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ABSTRACT 
 
 
Background: Ex vivo lung perfusion (EVLP) has since its introduction in clinical practice 
experienced a rapid expansion and made more organs available for transplantation. Different 
protocols and strategies have been implemented at transplantation centres around the world.  
Aims: In an experimental setup in pigs, the effect of haemofiltration during EVLP on lung function, 
perfusate oncotic pressure and lung weight (paper I), was evaluated, and two clinically used 
strategies for EVLP were compared, with respect to lung function, metabolism, inflammatory 
response, oxidative stress, and cell viability (paper II). To assess the clinical outcome of patients in 
Gothenburg and Copenhagen undergoing lung transplantation after EVLP they were compared to 
a contemporary control group (paper III). Correlations between lung physiologic variables during 
EVLP and short-term clinical outcome in lung transplant recipients were assessed, with the 
intention to identify variables during EVLP predicting post-transplantation outcome.  
Methods: In paper I, pulmonary oedema was induced in pigs, and lungs randomized to EVLP with 
or without haemofiltration. Oncotic pressure, lung performance and weight were measured before 
and after EVLP. In paper II porcine lungs were harvested and randomized to EVLP according to 
either of two clinically used protocols. The groups were compared before and after four hours of 
EVLP. In paper III lungs not accepted for donation, but with potential for improvement, 
underwent EVLP and were transplanted if predefined criteria were met. Outcome was compared 
to a control group of patients transplanted with conventional donor lungs. Variables during EVLP 
were examined for correlation with short-term outcome after lung transplantation in paper IV. 
Results: Haemofiltration during EVLP increased oncotic pressure and decreased lung weight 
compared to EVLP without haemofiltration, but without effect on lung oxygenation capacity in 
either group (paper I). There was a trend towards more lung oedema formation in the acellular, 
open left atrium group, but otherwise there were no differences between groups (paper II). Patients 
receiving lungs after EVLP had a lower PaO2/FiO2 ratio at arrival in the intensive care unit (ICU), 
longer time to extubation and spent longer time in ICU, however without difference in lung 
function at one year or survival at intermediate follow-up (paper III). No correlations could be 
found between variables measured during clinical EVLP and short-term outcome in lung transplant 
recipients (paper IV). 
Conclusions: Haemofiltration during EVLP may decrease pulmonary oedema. No major 
differences in effect could be established between the two clinically most used methods for EVLP. 
Outcome in patients transplanted with lungs after EVLP was comparable to patients receiving 
conventional lungs at intermediate-term follow-up. There were no clear correlations between 
commonly measured variables during EVLP and short-term outcome. 
Keywords:  
Ex vivo lung perfusion, EVLP, lung transplantation 
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SUMMARY IN SWEDISH 
SAMMANFATTNING PÅ SVENSKA 
 
 
Lungtransplantation är en etablerad slutgiltig behandling för patienter med terminal 
andningssvikt av olika genes. Långtidsresultaten är goda, och patienter transplanterade 
vid Sahlgrenska Universitetssjukhuset har en femårsöverlevnad på omkring 80%, vilket i 
en internationell jämförelse är mycket bra. 
Tillgången på organ är dock en begränsande faktor och trots ett långsiktigt arbete för att 
öka tillgången på donerade organ, genom bättre urvalsprocesser och användande av 
marginella organ från fler donatorer, är det fortsatt kö till lungtransplantation. Andelen 
multiorgandonatorer som donerar lungor varierar stort mellan olika centra, och det 
föreligger ett behov av att öka andelen organ som kan tas tillvara.  
Ex-vivo lungperfusion (EVLP) utvecklades som en metod för att utvärdera lungor 
utanför kroppen, initialt beskrivet av Stig Steen och kollegor 2001. De beskrev i en studie 
hur lungor transplanterades från en hjärtdöd donator till en recipient efter att lungorna 
utvärderats med hjälp av EVLP. EVLP har sedan dess genomgått en snabb utveckling 
och används nu kliniskt på ett stort antal lungtransplantationscentra världen över. Man 
kan, när man tror att patologin är reversibel, utvärdera, bedöma och optimera marginella 
organ, för att därefter ta beslutet att transplantera. Lundprotokollet som perfunderar med 
blodkroppsinnehållande perfusat (cellulärt perfusat) och öppet vänster förmak, samt 
evaluerar under fullt flöde, var det första protokollet beskrivet av Stig Steen. 
Torontoprotokollet som perfunderar med acellulärt perfusat i en sluten krets och 
evaluerar vid lägre tryck och flöden, beskrevs 2008, och har därefter blivit tongivande. 
Ytterligare ett protokoll, det s.k. OCS-protokollet, som möjliggör EVLP under transport, 
har utvecklats. 
Utöver möjligheterna att noggrant utvärdera funktionen hos lungorna, erbjuder EVLP 
vissa terapeutiska möjligheter. Man kan ”lufta upp” sammanfallna lungdelar under ögats 
överinseende, inspektera (bronkoskopi) och suga rent i luftvägarna, samt genom att 
perfundera med en särskild, för ändamålet framtagen lösning, med hyperonkotiska 
egenskaper, reducera vätskeansamling i lungorna (lungödem). 
I arbete I visades i en djurexperimentell studie på grislungor, i vilka lungödem 
framkallades genom att strypa det venösa avflödet från lungorna och ge stora mängder 
kristalloid vätska samtidigt, att man genom att koppla ett hemofilter till perfusionskretsen 
under EVLP, och hemofiltrera perfusatet, kunde öka det kolloidosmotiska trycket i 
perfusatet och därmed öka den ödemreducerande effekten av EVLP. 
X 
I arbete II jämfördes, i en djurexperimentell studie, de två förhärskande strategierna för 
EVLP, Lund- och Torontoprotokollen, så som de kliniskt appliceras i Göteborg 
respektive Wien. Hälften av lungparen randomiserades till vardera gruppen och 
genomgick 4 timmar EVLP, enligt respektive protokoll. Organen utvärderades avseende 
vikt och ödemutveckling, lungfunktion, inflammatoriskt svar, ischemi-reperfusionsskada 
och histopatologiskt utseende. Några avgörande skillnader mellan metoderna kunde inte 
påvisas. 
I arbete III, studerades utfallet på kort och lång sikt efter transplantation med lungor som 
genomgått EVLP, hos 54 recipienter, jämfört med en samtida grupp patienter som 
transplanterats med konventionella lungor. Tid till extubation och tid på IVA var 
signifikant längre hos patienter som fått lungor som genomgått EVLP, men det var ingen 
skillnad i tid till utskrivning från sjukhus, lungfunktion efter ett år eller överlevnad utan 
re-transplantation. 
I arbete VI, studerades, som ett led i att bättre förstå vilka faktorer under EVLP som 
påverkar lungornas funktion i recipienten efter transplantation, korrelationen mellan ett 
antal parametrar under EVLP med tre utfallsmått efter transplantation, första PaO2/FiO2 
vid ankomst till IVA, tid i ventilator och tid på IVA. Vi kunde inte finna några signifikanta 
korrelationer, och i uni- och multivariat analys fanns inte några samband mellan det vi 
vanligen mäter under EVLP och korttidsresultaten efter transplantation.  
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INTRODUCTION 
 
 
Lung transplantation  
 
In 1963, Hardy and colleagues in the USA, reported the first human lung transplantation, 
with lungs retrieved from a donor after cardiac death, on a convict with lung cancer and 
obstruction of the distal airways with recurring pneumonias.2,3 This first patient survived 
18 days after transplantation, but subsequently died due to renal failure. Over the coming 
years, few transplantations were performed worldwide, with disappointing outcomes.4 In 
1970 a review of 23 lung transplantations performed up until then, reported only one 
patient surviving longer than a month.5 In that single case, the patient died after 10 
months in what was described as chronic rejection.6 Poor healing of the airway 
anastomosis, secondary to the prevailing immunosuppressive regimes with high doses of 
prednisolone, impeded anastomotic site healing and resulted in poor survival.7 
The introduction of cyclosporine to the immunosuppressive arsenal, with significant 
improvements in survival after kidney and liver transplantation,8 triggered new interest 
into heart-lung and lung transplantation. The advent of cyclosporine enabled steroid 
doses to be kept considerably lower, and this, together with improved surgical techniques, 
promoted anastomotic site healing.9 
Successful combined heart-lung transplantation performed in 1981 indicated that 
transplanted lungs could function in a recipient.10 In 1983 the Toronto Lung Transplant 
group performed the first successful single lung transplantation, in a 58-year-old man with 
pulmonary fibrosis, still alive at the time of publication of the results in 1986.11 At the 
same centre, the first double lung transplantation was performed in 1986 in a 46-year-old 
woman with emphysema. She survived until 2001, for almost 15 years, and succumbed to 
unrelated illness.12 
These events laid the foundation for a rapid development and increasing numbers of lung 
transplantations were performed. From about 45 worldwide in 1987, increasing gradually 
to over 1400 yearly in the mid-nineties, to over 4000 reported yearly to the International 
Society for Heart and Lung Transplantation (ISHLT) Registry in recent years. A total of 
over 60000 transplantations had been reported to the registry up until 2016. Over time, 
the proportion of double lung to single lung transplantations has increased steadily. 
Numbers of double lung transplantations are increasing and contributing to the upward 
trend over time in total yearly numbers of performed transplantations, while numbers of 
single lung transplantations are remaining fairly stable over the years. The continuous 
upward trend in total yearly numbers of transplantations has plateaued over the last few 
years.13 
2 
The most frequent indication for lung transplantation is chronic obstructive pulmonary 
disease (COPD), with or without α-1-anti-trypsin deficiency, contributing to 36% of all 
cases, followed by the broad category of interstitial lung disease or pulmonary fibrosis, 
contributing to 30% of the cases. The third most common indication, in 18% of the cases, 
is bronchiectasis, most often related to cystic fibrosis. A range of other less common 
disorders make up the remainder, including pulmonary arterial hypertension, sarcoidosis, 
lymphangioleiomyomatosis, obliterative bronchiolitis, connective tissue disease and 
cancer.13 
Over the years, outcome has improved, due to a multitude of factors; better surgical 
technique, improvements in anaesthesia and intensive care, refined immunosuppressive 
therapy, more adequate donor and recipient selection. However, outcome in modern days 
are far from ideal, with chronic rejection now being the main obstacle to better long-term 
survival.14,15 Although short-term and 1-year survival has steadily increased, median 
survival times have plateaued, with the 5-year survival being similar between 1999-2008 
(55%), compared to 2009-2015 (57%). Median unconditional survival time between 1999-
2008 was 6.1 years after transplantation.13 In certain groups however, long-term median 
survival over 10 years has been achieved.16 
Lungs, as opposed to other solid organs, have to function more or less directly after 
transplantation, despite the trauma inflicted during cold ischemia and transportation. The 
extent of ischemia-reperfusion injury during this process may led to short-term failure 
expressed as primary graft dysfunction (PGD) with the development of tissue oedema, 
pulmonary infiltrates, and reduced oxygenation capacity.17-20 Improvements in lung 
preservation techniques have come a long way in minimizing these effects.21 
Shortage of suitable donor organs still remains a major limitation to extending the 
possibility of lung transplantation to even more patients. Patients are still waiting in vain 
for new organs, there is a substantial waiting-list mortality, and there are many more 
patients with co-morbidities that would benefit from lung transplantation but that, due to 
shortage of donor lungs, currently are not even considered for it. Lung transplantation 
compared to other solid organs has a relatively low organ procurement rate with only as 
little as 15-20% of organs being harvested in multi-organ brain dead donors, in the USA 
and United Kingdom.22-24 Numbers are however higher in certain centres; in Gothenburg 
data from the time period of 2008-2017 indicates that 36% of multi-organ donors donate 
lungs. Kotecha et al published a study in 2017 achieving an overall donor use of 41% 
using extended criteria donor lungs.25 Despite this, there is still a demand-supply 
mismatch, and lungs from multi-organ-donors are used for transplantation much less 
often compared to other solid organs such as the liver and the kidneys. 
Ideal lung transplant donor acceptability criteria according to the ISHLT were published 
in 2003.26 The donor should be ≤ 55 years of age; ABO compatible; have a clear chest 
radiograph; PaO2/FiO2 mmHg > 300 at a FiO2 of 1.0; a tobacco history of less than 20 
pack-years; no chest trauma; no evidence of aspiration or sepsis; no prior 
cardiopulmonary surgery; a sputum Gram stain without organisms; and absence of 
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purulent secretions at bronchoscopy. These rather strict criteria together with the lungs’ 
inherent susceptibility to injury, may in many instances lead to a too conservative 
approach and low utilization rate. Extended criteria accepting organs not fulfilling all 
above mentioned criteria have been implemented and shown to not result in inferior 
clinical outcome, thereby increasing numbers of potential donors.25,27-29 However, 
accepting more marginal organs increases risk and may lead to a more complicated post-
operative course.30,31 
Donation after brain death is currently the largest pool of donors. Several factors during 
the death-process and the subsequent management of the brain-dead donor can 
contribute to lung injury. Trauma, aspiration, ventilator-associated pneumonia and sepsis, 
ventilator-induced lung injury through volume- and barotrauma, atelectasis, oxygen 
toxicity and volume overload are all prevalent causes of injury.  
Inherent to the brain-death process is a cytokine storm, inducing a systemic inflammatory 
response and lung injury similar to that of acute respiratory distress syndrome (ARDS).32 
A catecholamine surge during the brain death process, in an attempt by the body to 
maintain cerebral perfusion, induces severe hypertension with concomitant increased left-
sided heart pressures, leading to neurogenic pulmonary oedema.33 
To expand the possible donor pool further, there has been resurgence of interest in 
donation after cardiac death (DCD).34 In 1995 D’Alessandro et al reported the first 
successful DCD donor lung transplantations as part of a program with controlled 
(withdrawal of life support in the ICU) DCD.35 Since then several centres worldwide have 
introduced DCD programs, primarily in the setting of controlled donation after 
withdrawal from life support, with encouraging results, as a way of increasing donor 
numbers.34,36 In Sweden DBD has been the only option up until now, however a DCD-
programme is under way of being implemented. 
Ex vivo lung perfusion 
 
Stig Steen and the early days 
 
During the twentieth century, in conjunction with the development of cardiopulmonary 
bypass and growing interest in transplantation, perfusion and preservation of organs, 
perfusion of thoracic organs was studied. Early attempts of perfusing lungs resulted in 
deteriorating function and oedema formation.37 This era has been thoroughly described 
by Sanchez et al.38  Normothermic ex vivo lung perfusion (EVLP) in the setting of auto 
perfusion of the heart and lungs for preservation during distant procurement was studied 
in a clinical setting by Hardesty et al. in the 80’s, but was abandoned due to lower 
outcomes.39 
Stig Steen and colleagues developed EVLP in the latter part of the 1990’s in the context 
of donation from non-heart-beating donors.40-43 In 2001 they reported, after careful 
ethical consideration, the successful single lung transplantation of a right lung from a non-
4 
heart-beating donor to a 54-year-old recipient with COPD, after EVLP of the organs.44 
Crucial to this success was the development of Steen Solution™, a buffered perfusate 
containing a high albumin concentration with optimal colloid osmotic pressure, which 
allowed for perfusion at physiologic pressures without the development of pulmonary 
oedema, later also having been attributed antioxidative and cytoprotective effects.45-47 
Steen solution™ have since then been widely used in all three prevailing EVLP protocols, 
although subsequently, in the OCS Lung protocol Steen solution™ has been substituted. 
In part due to its high cost, alternative solutions have been investigated.48  
In 2005 the Lund group performed the first transplantation of an initially rejected lung 
after seventeen hours of EVLP reconditioning. The donor was brain-dead following a 
traffic accident and the lung subjected to EVLP was oedematous, with bleeding spots and 
atelectasis. However transplantation was successful and computed tomography (CT) after 
three months showed a normal lung.49 A following study by the group in 2006 reported 
the ex vivo evaluation of six donor lungs deemed non-acceptable for transplantation.50 In 
2009, Ingemansson et al. followed up on these results with a series of 6 patients receiving 
double lung transplantation after EVLP, from nine marginal donor lung pairs evaluated 
with EVLP.51 
A second study evaluating EVLP as a method for assessing transplantability was 
published 2006 by Egan et al.52 They evaluated lungs from six brain-dead donors, using a 
similar setup as the Lund group. In a porcine experimental setup Erasmus et al. used 
EVLP to evaluate two different clinical non-heart-beating donor protocols, and whether 
EVLP could be used for 6 hours of ex vivo preservation. They experienced stable gas 
exchange during this period of EVLP, but pulmonary artery pressures and ventilation 
pressures were increased.53  
In 2008 Cypel et al. in Toronto published a paper on extended EVLP assessment of lung 
function using a new protocol, the “Toronto protocol”,54 differing in several aspects from 
the one developed earlier by Steen et al., being the starting point for one of the more 
influential EVLP strategies. It put a stronger emphasis on the reconditioning properties 
of EVLP, aiming to extend the timeframe of EVLP, and in 2009 they published a study 
comparing extended cold preservation with prolonged (12 hours) EVLP.55 
Rational and indications for clinical EVLP 
 
The rationale behind EVLP is to acquire a window of time to evaluate and assess lungs 
of marginal quality, outside the body of the donor, when it is believed that organ 
pathology could be reversible, using this time to “recondition” the organs.50,56  In this 
way, it is possible to evaluate, and in many cases subsequently transplant many organs 
that previously would have been discarded, thereby substantially increasing the availability 
of transplantable organs.57,58  
 
Neurogenic pulmonary oedema developing in DBD donors is reversible,33,59 however 
measures taken to minimize it in vivo, using diuretics and fluid restriction, may not always 
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be successful. During EVLP, the lungs are re-warmed to body temperature and perfused 
with a hyperoncotic solution, believed to promote the clearing of oedema during the 
EVLP procedure.50 However, experiences from Gothenburg somewhat questions this 
hypothesis, as lungs may both gain or lose weight during EVLP.60 In an effort to further 
enhance the oedema-reducing properties of EVLP, Wallinder et al. published a case-
report on haemofiltration during EVLP.61  
Further, during EVLP, it is possible to directly examine the tissues for any signs of trauma, 
tumour, infection or atelectasis, as well as to perform a collapse-test assessing the 
compliant properties of the lungs. It is possible to under direct vision re-expand any 
atelectatic tissue, atelectasis that in vivo often is not being responsive to recruitment 
manoeuvres. Bronchoscopy can be performed, the bronchial tree inspected for evidence 
of inflammation, infection and secretions, and bronchial secretions can be cleared and 
sent for further analysis. The lungs can be weighed and conclusions drawn from weights 
before and after EVLP.38 
Pulmonary vascular resistance can be calculated from pulmonary artery pressures and 
perfusate flow measurements and followed over time. Ventilatory variables such as airway 
pressures and calculated lung compliance can be recorded and followed over time. 
Perfusate samples can be taken for blood-gas analysis and further testing. 
Criteria for EVLP differ between institutions. However, gross trauma and established 
irreversible lung damage is considered a contraindication. In the study in 2012 by Cypel 
et al., lungs without evidence of irreversible lung damage, with an oxygenation index  
(PaO2/FiO2) less than <300 mmHg, and radiologic signs of extensive lung oedema were 
included.56 In Gothenburg, lungs with a PaO2/FiO2 of less than <40 kPa with radiologic 
signs of infiltrates suggestive of pneumonia, lung infarction, or aspiration were considered 
for EVLP.1 
The EVLP circuit and the clinical protocols 
 
The typical EVLP system include a perfusion circuit with a pump, a gas-exchange module, 
a heater-cooler unit for heating or cooling the perfusate, a leukocyte filter,62-64 a reservoir 
and tubing connecting the parts together, along with cannulas connecting the circuit to 
the lung (Figure 1). Also included is an endotracheal tube connecting the lungs to a 
ventilator and a gas supply (both oxygen and air to the ventilator, and a de-oxygenating 
gas to the gas-exchange module incorporated into the circuit). A temperature probe for 
recording perfusate temperature is included as well. Left atrial return of perfusate from 
the lungs can be either collected passively into a reservoir (Lund protocol) or through a 
closed cannula sutured to the left atrial remnant (Toronto protocol). Pumps can be either 
roller, centrifugal or piston-operated. 
Initially constructed with in-house supplies from the perfusionist’s department, four 
different commercialized devices have now been developed for EVLP, incorporating all 
necessary techonology into one unit, together with disposable materials adapted for each 
6 
system. These devices are the Vivoline LS1 (Vivoline), the XPS (XVIVO Perfusion AB), 
Lung assist (Organ assist) and Organ Care system Lung (OCS). They all apply a certain 
protocol of EVLP, according to Lund, Toronto or OCS. 
Three predominant protocols for the execution of EVLP have been developed (Table 1, 
adapted from Andreasson et al65 and Maksidi et al66). The original, developed in Lund by 
Stig Steen et al. and the protocol developed by the Toronto group, differ in the use of red 
blood cells in the perfusate fluid, the flow at which evaluation is performed, the type of 
pump used, and whether pulmonary venous blood drains passively from the lungs in an 
open circuit or through a closed circuit with both pulmonary artery (PA) and left atrial 
(LA) cannulas, and the application of a LA pressure.67,68  The Toronto protocol advocates 
a low flow strategy and acellular perfusate, whereas the Lund protocol employs red blood 
cells added to the perfusate and evaluates at physiological perfusate flows. All protocols 
include corticosteroids to suppress immune response and broad-spectrum antibiotics in 
the perfusate to treat any concomitant infection.69,70 
In both the Lund and the Toronto protocols, lungs are initially harvested, cold-flushed 
and kept in static cold storage, before being subjected to EVLP. After completion of 
EVLP, awaiting transplantation, lungs are usually cooled and put in cold storage, however 
this practice has been questioned.71 OCS differs in that aspect, providing EVLP 
opportunities immediately after harvesting and pulmonary flush, during transportation, 
thereby intending to minimise lung ischemia time.72 Protocols have over time been 
adapted and developed locally and differ from centre to centre in some aspects. 
The decision to proceed with transplantation after EVLP is based on the performance of 
the organs in several different aspects: an adequate lung oxygenation capacity with an 
adequate PaO2/FiO2 ratio (>40 kPa/>300 mmHg) during the evaluation phase; stable 
Figure 1. 
A schematic drawing of the typical EVLP unit. 
Adapted from Wallinder et al1 
PA (pulmonary artery), LA (left atrium), HCU 
(heater/cooler unit). 
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hemodynamic and respiratory variables (pulmonary vascular resistance (PVR), peak 
airway pressures, and lung compliance), the absence of any macroscopic signs of 
pneumonic infiltrates, lung infarctions or other gross pathology, and a normal collapse 
test indicating normal elastic and compliant properties of the lungs. 
Clinical results - the Lund protocol 
 
The Lund protocol was primarily designed as an assessment system, evaluating lungs 
under physiologic conditions after rewarming, given a sufficient time for reconditioning. 
The lungs are recruited and ventilated, bronchoscopy performed, the inflammatory 
burden decreased by a leukocyte filter added to the circuit, time given for antibiotics and 
glucocorticoids to have their effect, and time given for the hyperoncotic perfusate to 
reduce oedema. Time on EVLP is not spent longer than needed if the organs are deemed 
acceptable for transplantation, however time can be extended if there still is potential for 
further improvement.1,49,73 The initial clinical series published by Ingemansson et al. has 
been described above.51 The same group followed up with a review of their clinical 
experience in 2011.45 
Wallinder et al. published early results from a clinical EVLP program in Gothenburg, 
based on the Lund protocol, in 2012.1 Soon after that, an EVLP program based on the 
same protocol was initiated in Copenhagen.74 Wallinder et al. have in several publications 
presented the outcome compared to a contemporary control group of conventional lung 
transplantations.60,75 Long-term outcome in patients receiving lungs after EVLP, have in 
these studies been shown to be comparable to conventional lungs. 
Table 1 - Three different protocols for EVLP
Lund Toronto OCS
Perfusion
Target flow 100% of CO, 70 ml/kg/min 40% of CO 2-2.5 l/min
PA pressure (mmHg) ≤20 ≤15 ≤20
LA pressure open LA 3-5 open LA
Type of pump Roller Centrifugal Pulsatile
Perfusate Steen Solution with RBC Steen Solution OCS lung solution
with RBC
Ventilation
Tidal volume (ml/kg) 6-8 7 6
Frequency 10-15 7 10
PEEP (cm H2O) 5 5 5
Fraction inspired oxygen 0.5 0.21 0.21
Temperature °C
Start of ventilation 32 32 32
Start of perfusion 15 25 32
Start of evaluation 37 37 37
PA = pulmonary artery; LA = left atrium; CO = cardiac output; RBC = red blood cells; PEEP = positive end-expiratory pressure
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Valenza et al. in Milano, published in 2012 a small study consisting of two patients on 
ECMO receiving marginal lungs after EVLP reconditioning, compared to a small 
contemporary control of conventional transplantations, with similar results between 
groups despite the critical state of the recipient population.76 They returned in 2014 with 
another study reporting transplantation after EVLP in seven cases compared to 28 
controls with no significant differences in outcome and survival.77 
Fildes et al. in Manchester compared early outcome up to one year after transplantation 
in a group of 9 patients transplanted with lungs after EVLP compared to a temporary 
control group without finding any significant differences in early clinical outcome 
between the two groups.78 
Fisher et al. published results from the Develop UK study in 2016.79 In a non-randomized 
study of transplantation after EVLP versus standard-criteria lungs, only 18 out of 53 
donor lungs were subsequently transplanted, and results showed a non-significant lower 
one-year survival in the EVLP, as well as, higher rate of early graft injury and 
postoperative ECMO support, at increased cost. 
Clinical results - the Toronto protocol 
 
The Toronto protocol, developed by Keshavjee and colleagues, has, since its introduction, 
gained widespread use all over the world.54,56,57,80-82 In addition to the evaluative 
possibilities of EVLP, focus is also on prolonging the perfusion with the possibility of 
treating and better reconditioning the organs.83 This approach is reflected in their early 
publication on repair of human donor lungs by IL-10 gene therapy.84 Just recently, the 
Toronto group, almost a decade later, published a study on the same subject, in a large 
animal model, demonstrating that ex vivo treatment with AdhIL-10 is safe and improves 
post-transplant lung function after EVLP.85  
With a view to improving the Lund protocol, they apply acellular perfusate with the 
intention to avoid damaging haemolysis, a lower target flow to reduce any oedema 
formation and a closed circuit with the maintenance of a positive LA pressure through a 
specifically adapted LA cannula.86 
Being the first prospective clinical trial in EVLP, the HELP trial, published by Cypel et 
al. in 2011 was ground-breaking.56 Twenty out of 23 sets of lungs considered high-risk 
were transplanted and outcome compared to a group of 166 patients receiving 
conventional lungs. No differences were seen with regards to primary graft dysfunction 
(PGD), days on ventilator, time in ICU or hospital- and 30-day mortality. In 2012 the 
same group reported their experience of 50 consecutive transplantations after 58 EVLP 
evaluations (86% conversion rate), with lungs from both DCD and DBD donors, 
compared to a contemporary control group.57 Short-term outcome were similar in both 
groups, and one-year survival was 87% in the EVLP group compared to 86% in the 
control group. 
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Aigner et al. in Vienna published a study in 2012 on 9 double-lung transplantations after 
EVLP assessment, compared to a control group of 119 patients, reporting similar short-
term results between groups.87 The same year, Zych et al. in Harefield, after having 
published a case report on a successful transplantation after EVLP in 2011,88 reported 
transplantation of 6 pairs of donor lungs out of 13 EVLP evaluated, with a 100% 3-month 
survival rate.89 
A retrospective study of independently collected data from Toronto, Paris and Vienna, 
encompassing 125 EVLP evaluations was presented at the ISHLT meeting in 2013.90 
Both DCD and DBD donors were included in the cohort. Lungs were transplanted in 
103 cases, mounting up to a conversion rate of 82.5%. Good short- and intermediate-
term outcome was reported, with a one-year survival rate of 88%. 
The Paris group published their cohort in 2014, consisting of 31 double lung 
transplantations after 32 EVLP evaluations, compared to a contemporary control group. 
They experienced significantly longer times in ICU and in hospital stay in the EVLP 
group, but one-year survival was excellent in both groups, 93% and 91% respectively.91 
Turin reported no difference in incidence or severity of PGD in eight cases of 
transplantation after EVLP compared to a control group of 28 patients.92 
The result of the NOVEL trial,93 a prospective, non-randomised trial in six centres in the 
USA was presented in 2014.94 76 EVLP:s were performed and 42 were transplanted (55% 
utilization rate), and compared to a contemporary control group. Early outcome after 
lung transplantation and one-year survival were not significantly different between 
patients that received EVLP compared to standard criteria lungs. 
Maryland reported short-term outcome data in 11 transplanted grafts out of 17 evaluated 
with EVLP (65% conversion rate). There were no severe PGD at 72 hours in their 
material.  
In 2017, in a retrospective study of data from the Toronto Lung Transplant Program 
database, Yeung et al. compared outcome in patients receiving lungs exposed to EVLP 
for more than 12 hours (mean 14.6 hours) compared to a control group with shorter 
EVLP-times than 12 hours (mean 6.7 hours).95 Longer EVLP did not significantly affect 
short-term outcome. This is in line with the Toronto approach to EVLP, viewing EVLP 
not just as a means of evaluation, but also as a treatment opportunity, and a method of 
increasing flexibility around the transplantation process. 
In 2017 Slama et al. published a study comparing two groups of donor lungs, that both 
met standard inclusion criteria for transplantation.96 One of the groups underwent EVLP 
prior to transplantation, and the other group was transplanted in a standard fashion 
Functional results and perioperative outcome in the EVLP group were comparable to 
those achieved with standard donor lung preservation techniques. It was concluded that 
EVLP is an option to safely extend total preservation time. 
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Under way is the large multicentre “Normothermic EVLP As An Assessment Of 
Extended/Marginal Donor Lungs study”.97 
Although short- and intermediate-term outcome has been widely published, long-term 
data is scarcer. In 2015 the Toronto group published a retrospective study of all 
transplants performed between 2008 and 2012 and reported up to five-year survival-rates 
that were similar between groups, as were freedom from chronic lung allograft 
dysfunction (CLAD), rejection episodes, 6-minute walk distance and FEV1.98 
Clinical results - Hannover/Madrid – OCS 
 
In 2012, Warnecke et al. presented a new application of EVLP, evaluating the 
normothermic preservation and transportation of standard criteria lungs on a portable 
EVLP system, the Organ Care system™ Lung (Transmedics, Andover, USA).72 Twelve 
pairs of standard lungs were preserved under normothermic conditions in this study, as 
opposed to traditional cold preservation. Short-term outcome was non-inferior compared 
to control. 
The OCS protocol, in line with the Lund protocol, applies a cellular perfusate and open 
LA, but in agreement with the Toronto protocol, limit flows. As opposed to the other 
two protocols, Steen Solution has been replaced by a solution made by the system 
manufacturer. 
The principal initial focus of OCS was the transportation of standard criteria lungs using 
normothermic EVLP, setting it apart from the Lund and Toronto protocols that were 
primarily designed as protocols for evaluating and reconditioning marginal donor lungs, 
in-house. The INSPIRE-trial was a prospective randomized multicentre study comparing 
outcomes of standard criteria lungs preserved and transported by either normothermic 
EVLP in the OCS system or standard cold preservation.99,100 The use of the OCS Lung 
in the reconditioning of marginal lungs was studied in the EXPAND trial, results of which 
are to be presented at the 2018 ISHLT meeting. In 2016, Zeriouh et al. reported a study 
comparing short- and medium-term outcome in a group of 14 organs preserved with the 
OCS Lung, compared to a control group of 308 patients transplanted after cold 
preservation. Patients in the OCS group had a significantly better postoperative FEV1 at 
3 and 6 months, and similar outcome in terms of cumulative survival and freedom from 
bronchiolitis obliterans syndrome (BOS).101 Schmack et al. published a recent review in 
2016 on the OCS Lung concept.102 The focus of this thesis is, however, on the Lund and 
Toronto protocols and their application. 
EVLP in special cases 
 
Brown et al. reported a case of EVLP on donor lungs with pulmonary embolism, in which 
lung oxygenation capacity increased and PVR decreased during EVLP, suggesting that 
they could have been acceptable for lung transplantation.103 A second case report on the 
same subject, using urokinase during EVLP, and subsequently successfully transplanting 
a pair of lungs was published in 2014.104 Daine et al. published a case on successful 
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transplantations after EVLP in a series of five DBD donors after asphyxia by hanging.105 
Patil et al. used EVLP to evaluate lungs that inadvertently during the harvesting procedure 
were flushed with very high PA pressure.106 Costa et al. evaluated EVLP of lungs from 
12 donors with a history of cardiac surgery with successful results and outcome.107 De 
Wolf et al. used EVLP to gain time while waiting for a negative result in cross matching 
in hyperimmunized patients, then moving forward with transplantation in three patients, 
with all patients alive after three years.108 
Establishing the baseline in human EVLP and predicting outcome 
 
A series of descriptive publications with the primary aim of establishing baseline 
parameters during EVLP have been presented. There has over time also been a growing 
interest in investigating factors and markers during EVLP, predicting successful outcome 
after transplantation. 
In 2011, Sadaria et al. established a cytokine expression profile in human lungs undergoing 
normothermic EVLP.109 The same year, Koike et al. reported on lactate metabolism, 
during acellular normothermic EVLP, concluding that a gradual increase due to reduced 
clearance was to be expected.110 In 2013, George et al. presented physiologic and 
biochemical profiles of clinically rejected lungs on EVLP.111 
In 2015 Machuca et al. in Toronto, using perfusate samples from 50 EVLP procedures in 
human lungs collected after 1 and 4 hours of EVLP, investigated the expression of 
cytokines, chemokines and growth factors. They showed that perfusate biomarkers could 
potentially be used for more precise donor lung selection improving outcome after 
transplantation.112 In a contemporary study they evaluated the endothelin-1 pathway as 
potential predictors for lung function.113 
There is a great interest in finding biochemical markers or combinations of markers 
during EVLP that could predict the transplantability of the organs. None has so far 
reached clinical use. Research is active in this field, and a range of preliminary smaller 
studies have been published during 2017.114-118 
EVLP as an experimental platform in animal studies 
 
Although having been extensively applied in clinical practice for the last decade, animal 
studies was the first step, binding theory and practice together, needed for the 
development of the protocols later to be tested in human research. EVLP is still a novel 
technique in constant development, and a steady stream of experimental animal studies 
into different aspects of EVLP have emerged in parallel with clinical progress over the 
last decade. In this section a brief description of the findings of the majority of these 
experimental studies is given. 
Because of their similarity to human lungs, albeit not identical, porcine lungs have been 
the most extensively used.119,120 There are, however, also experimental studies performed 
on lungs from other animals, such as rat, mice and dog.121-125 
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Emaminia et al. investigated in a small study in 2011 the use of an adenosine A2A agonist 
during EVLP, suggesting a positive effect on oedema and ischemia-reperfusion injury, 
confirming these findings in a study in mice in 2015.123,126 In 2016, on the same theme, 
they published a second study in mice on the attenuation of ischemia-reperfusion injury 
by an adenosine A2B antagonist.127 Several recent studies have reported positive results 
after adding agents to the perfusate, for example by inhibiting NF-κB128 or by adding 
trimerazidine to attenuate ischaemia/reperfusion injury during EVLP.129 None of these 
experimental approaches has yet been implemented into clinical practice. 
Meers et al. published in 2011 the work on an aspiration model in swine and demonstrated 
the feasibility of assessing the organs by EVLP.130,131 They then used this model to 
compare steroids to macrolides to improve gas-exchange in caustic-injured lungs.132 In 
2014 Khalife-Hocquemiller et al., in an aspiration-model with gastric acid, found that 
surfactant attenuated lung injury during EVLP.133 Last year in a similar study in pigs, 
Nakajima et al. reported better outcome after lung lavage and surfactant replacement 
during EVLP after gastric-acid induced lung injury.134 
Valenza et al. investigated glucose consumption during EVLP, and found that increased 
glucose consumption correlated with worse lung function.135 Following up on these 
results, in 2012, they showed that salbutamol infusion during EVLP was associated with 
lower pulmonary pressures and better lung mechanics.136 These findings were confirmed 
in a canine study by Kondo et al. in 2015, showing that inhalation of salbutamol attenuates 
lung injury.122 A third study in 2017, in a canine model, by Hijiya et al. supported earlier 
findings.137 
The Toronto group performed prolonged EVLP during 12 hours in porcine lungs 
subjected to 24 hours of cold ischemia, whereby they organs were transplanted and 
evaluated in vivo.138 The organs developed oedema during EVLP and decreased 
compliance, and subsequently performed poor in vivo. The significant finding in this 
study was that ex vivo PO2 is a poor indicator of lung performance due to the linearization 
of the relationship between oxygen content and PO2 in acellular perfusate. The same 
group published an additional study, the same year, comparing ex vivo with in vivo 
intratracheal adenoviral vector gene delivery.139 
The poor reliability of PO2 alone in assessing lung function during EVLP is well known, 
especially using acellular perfusate, as shown in the above-mentioned study. Conditions 
are different using cellular perfusate, however, it has been shown that it is important to 
relate the PaO2/FiO2 ratio to the inspired fraction of oxygen.140 PaO2 is related to shunt 
fraction and depending on the extent of shunt the relationship between PaO2 and 
different FiO2 varies.141 Pablo et al. in Maryland have adapted their EVLP protocol to put 
stronger emphasis on compliance dynamics in decision-making during EVLP.142 
Okamoto et al. studied correlations between the PaO2/FiO2 ratio and airway and vascular 
parameters during cellular EVLP in both porcine and human lungs and found that airway 
parameters were complementary quantitative indicators of lung function in cellular 
EVLP.143 
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Thrombolytic therapy during EVLP in a rat model was studied in 2013 by Motoyama et 
al., and again in 2014.144,145 It has, as described above, been applied in clinical cases as 
well. 
Maignan et al. have studied measurement of exhaled carbon monoxide (CO) during 
EVLP, as a marker for ischemia reperfusion injury, showing a positive correlation 
between exhaled concentration of CO and the degree of ischaemia/reperfusion 
injury.146,147 
Pierre et al. evaluated in a porcine model the effects of extending EVLP-times, reporting 
increasing weight with increased time on EVLP. Results from this study could not in an 
experimental setting show benefit from additional time on EVLP, contradicting later 
clinical reports of successful outcome after extended EVLP in human lungs.148 
Noda et al. have published several experimental studies in rat, beginning with the 
establishment of a rat EVLP model in 2014.124 The same year they demonstrated that 
lung grafts on EVLP exhibited prominent pro-inflammatory changes and compromised 
metabolic profiles. It was possible to attenuate this by inhaling the lungs with hydrogen.149 
In a study in 2015, they compared a novel technique of dual EVLP, also including the 
bronchial artery circulation to the EVLP circuit, achieving superior outcome in this 
group.150 Recently they published a study on optimal O2 levels in the perfusate during 
EVLP. Deoxygenated perfusate exhibited significantly more inflammation with 
compromised cellular metabolic activity and compromised post-transplant outcomes.151 
In 2015, Harada et al. reported on a small study assessing the addition of a neutrophil 
elastase inhibitor to the perfusate, indicating that the inflammatory response may be 
attenuated and lung reperfusion injury be decreased.152 Lin et al. reported in 2017 positive 
results of adding alpha-1-antitrypsin to the perfusate.153 
In a study in rat, thermography was used to detect regional malperfusion during EVLP, 
in lungs with induced thrombi. Thermographical evaluation may, in contrast to prevailing 
modalities, detect regional damage in donor lungs.154 In 2017 Sage et al. reported on using 
real-time CT to assess organs during EVLP.155 
Martens et al. in a study in 2016 could not, in a porcine model, improve graft function 
using inhalation of argon or xenon gases during EVLP.156 In a succeeding study by the 
same group, exposing lungs to maximal xenon exposure, they again did not find support 
for this approach.157 Several studies have found support for protective effects of inhaling 
different agents during EVLP, such as sevoflurane.158  
Renewed interest in cytokine filtration to reduce accumulation during prolonged EVLP 
led Iskender et al. to publish a porcine study showing that cytokine removal decreased the 
development of pulmonary oedema and electrolyte imbalance. These findings contrast 
with the negative findings by Kakishita et al. back in 2010.159 
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Lately there has also been an interest into ventilation strategies applied during EVLP. In 
2017, Mehaffey et al. demonstrated superior results with airway pressure release 
ventilation during EVLP.160 The same year, Aboelnazar et al. presented a negative 
pressure ventilation model, where they could demonstrate decreased inflammation and 
less oedema formation during EVLP.161 
In 2017 Himmat et al. showed that a decrease in hypoxic pulmonary vasoconstriction 
during EVLP correlated with increased inflammation during extended EVLP.162 
Although most experimental studies have been performed according to either the Lund 
or Toronto protocol, some studies adopting OCS have emerged. Among them a study in 
prolonged EVLP using OCS Lung and comparing cellular and acellular perfusates.163 
EVLP in the context of DCD 
 
There is growing support of the use of EVLP after controlled DCD donation.57,164-166 In 
2015 Machuca et al. published a study evaluating the impact of EVLP on outcome after 
transplantation of donation after DCD lungs.167  Between 2007 and 2013, out of a total 
of 673 lung transplantations performed, 55 were DCD transplantations (excluding 
bridged cases from analysis in this study). Twenty-eight (51%) of the DCD cases 
underwent EVLP. Outcome after transplantation with organs from DBD compared to 
DCD donors was similar, up to five years after transplantation. Organs from DBD donors 
that were transplanted after EVLP presented shorter hospital stay and a trend towards 
shorter time on ventilator, but without any difference in survival. 
EVLP has been extensively used as an experimental platform evaluating different 
procedures and approaches to performing transplantation of lungs after DCD.168-174 
EVLP after DCD is however outside the scope of this thesis and will not be covered 
further.
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AIMS 
 
 
General aims 
 
The general aims of this thesis were to increase the understanding of ex vivo lung 
perfusion (EVLP) the way it is contemporarily performed according to two different 
strategies, to experimentally investigate refinements and additions to the procedure and 
to compare two established protocols. 
Additional aims were to review the clinical outcome of patients that had been transplanted 
with lungs that had undergone EVLP in two Scandinavian centres, and to investigate 
whether it could be established which parameters during EVLP matter the most for 
clinical outcome.  
Study aims 
 
I. To evaluate the effect of haemofiltration during EVLP on lung function, perfusate 
oncotic pressure, and lung weight as a measure of tissue oedema content, in a 
porcine model. 
II. To compare two clinically used strategies for EVLP with respect to lung function, 
metabolism, inflammatory response, oxidative stress, and cell viability, in a porcine 
model. 
III. To review the combined clinical short- and medium-term outcome of patients 
undergoing lung transplantation after EVLP in Gothenburg and Copenhagen and 
compare it to a contemporary control group of patients transplanted with 
conventional (non-EVLP) lungs.  
IV. To assess the correlations between several physiological variables during EVLP, 
with short-term outcome variables in 47 double lung recipients of EVLP-evaluated 
lungs, to identify which factors are the most important in predicting outcome after 
transplantation. 
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METHODS 
 
 
The animal experiments were performed at the Laboratory for Experimental 
Biomedicine, at Gothenburg University. Paper II is in collaboration with representatives 
of the Laboratory for Microbiology, Parasitology and Hygiene, Antwerp University, 
Antwerp, Belgium and the Department of Thoracic Surgery, Medical University of 
Vienna, Austria. Paper III and VI are in collaboration with Rigshospitalet in Copenhagen 
and the University of Copenhagen. 
Ethical considerations 
 
Papers I and II – experimental animal studies 
 
The experimental animal studies were performed following approval of The Animal 
Ethical Committee of the University of Gothenburg. The animals received care in 
compliance with the European Convention for the Protection of Vertebrate Animals 
Used for Experimental and Other Scientific Purposes (1986), the Principles of Laboratory 
Animal Care formulated by the National Society for Medical Research, and the Guide for 
the Care and Use of Laboratory Animals from the National Institutes of Health, USA. At 
the end of the experiments animals were euthanized by exsanguination. 
Papers III and IV – clinical studies 
 
The Human Ethics Committees of the University of Gothenburg and the University of 
Copenhagen approved the clinical studies. All patients were informed, both orally and in 
writing, and consented in writing, when listed for transplantation, to the possibility of 
receiving organs that had undergone EVLP. Participants were allowed to withdraw from 
the study at any time. The organs were matched according to standard criteria. 
Animal studies (papers I and II) 
 
Animals 
 
Swedish domestic pigs were supplied by a local breeder. All animals were delivered to the 
laboratory one week in advance of performing the study. A veterinarian supervised care 
and handling of the animals, before and during experiments. 
Twenty-two animals were included in Paper I, of which sixteen were subjected to 
induction of pulmonary oedema in vivo, and six controls were not. Two animals in the 
oedema induction group were excluded due to them developing severe right heart failure 
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and the inability to maintain study protocol targets. The remaining fourteen animals were 
randomized, in two equally sized groups, to EVLP either with or without haemofiltration.  
Twenty animals were included in Paper II, randomized to two equally sized study groups. 
Measurements during the experiments were when appropriate indexed to body surface 
area.175 
Anaesthesia and preparation 
 
The animals were fasted overnight, with free access to water. They received premedication 
while in stables, with an intramuscular injection of a combination of 0.06 mg/kg body 
weight (BW) dexmedetomidin (Dexdomitor, Orion Pharma AB, Sollentuna, Sweden) and 
5 mg/kg BW, respectively, of tiletamine hydrochloride and zolazepam hydrochloride 
(Zoletil, Virbac, Carros, France).  
The animals were then transferred to a preparation room and placed in the prone position.  
They were given an intramuscular injection of buprenorphine 0.03 mg/kg BW (Vetergesic 
vet, Orion Pharma Animal Health, Sollentuna, Sweden) and an intravenous catheter was 
placed in the ear.  Tracheal intubation was performed under spontaneous breathing. The 
pigs were subsequently transferred to the operating room and placed in the supine 
position on the operating table.  
Volume-controlled ventilation was initiated with a tidal volume of 10 ml/kg, a positive 
end-expiratory pressure (PEEP) of 0 mmHg (Paper I) or 5 mmHg (Paper II), and a FiO2 
of 0.5, adjusting the respiratory frequency to maintain end-tidal CO2 (et-CO2) in the 
normal range of 5-5.5 kPa, using a Servo Ventilator (Servo Ventilator 900C, Siemens-
Elema AB, Solna, Sweden). Anaesthesia was maintained throughout the experiment using 
isoflurane (Isoba Vet, Intervet AB, Sollentuna, Sweden) at a minimal alveolar 
concentration (MAC) of 1.3.  
Lung harvesting  
 
A cannula was inserted in the pulmonary artery and secured in place with a purse string 
suture, and the left atrial appendage was incised widely to allow for free drainage of the 
organ preservation fluid. The lungs were then perfused antegradely at a low perfusion 
pressure (<20 mmHg) with 2 litres of cold Perfadex (Vitrolife AB, Gothenburg, Sweden) 
with added isotonic trometamol, 0.35 ml (Addex-THAM 3.3 mmol/ml, Fresenius Kabi 
AB, Uppsala, Sweden), calcium gluconate, 1.4 ml (9 mg/ml) and nitroglycerin, 3 ml (5 
mg/ml, BMM Pharma AB, Stockholm, Sweden), to every litre of Perfadex. The lungs 
were harvested in a standard fashion and subsequently perfused retrogradely with an 
additional 2 litres of cold Perfadex with the above-mentioned additives. The lungs were 
weighed again and put in a bag of cold Perfadex. They were then stored at 8 °C for two 
hours.  
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Following 2 hours of cold ischemia the lungs were again weighed and again retrogradely 
perfused with an additional 1 l of Perfadex with the above-mentioned additives.  
Induction of pulmonary oedema (paper I) 
 
An arterial catheter was placed in the right femoral artery, using ultrasound-guided 
Seldinger technique. The same method was used to place an 8.5 Fr catheter introducer in 
the right external jugular vein, through which a Swan-Ganz catheter (Swan-Ganz 
CCOmbo, 7.5 F Edward Life Sciences, Irvine, California) was introduced and forwarded 
to the pulmonary artery under observation of the pulse pressure wave form. A 
temperature probe was placed orally. 
A median sternotomy was performed, and the pericardium was opened. A balloon-tipped 
catheter was placed in the left atrium (LA) through a small incision in the left atrial 
appendage and secured in place with a purse string suture. (Figure 2). 
An infusion of Ringers-acetate was initiated at a rate of 20 ml/kg BW/hour. The LA 
balloon was inflated gradually, while maintaining a pulmonary artery systolic pressure 
(PAs) of at least 50 mmHg, until a pulmonary capillary wedge pressure (PCWP) of 25-30 
mmHg was reached. The PCWP was then maintained in this range for the duration of 
two hours, adjusting the volume of the left atrial balloon as needed. Arterial blood gases 
(ABL 725 Radiometer, Copenhagen, Denmark), cardiac output (CO), heart rate, mean 
arterial pressure (MAP), PAs, mean pulmonary artery pressure (PAm), diastolic 
Figure 2. 
Image depicting an animal after sternotomy and placement of the left atrial balloon-tipped catheter, 
through the left atrial appendage. The catheter is yellow in colour and can be seen at the top of the 
image, rounding the left lateral border of the heart. The heart is markedly rotated to the left and the left 
atrial appendage cannot be seen in this picture.   
20 
pulmonary artery pressure (PAd) and PCWP, as well as, et-CO2, tidal volume and 
inspiratory plateau pressure, were measured and recorded (BeneView T8, Mindray 
Medical Int Ltd, Shenzhen, China) after sternotomy, before and after the induction of 
lung oedema. CO was measured using the cardiac output module of the BeneView T8, 
by bolus injections of cold saline. At each recording, CO was averaged over three 
measurements.  The animals were then exsanguinated to a cell saver (Autolog, Medtronic 
Inc, Minneapolis, USA) and the blood processed for use during the EVLP phase of the 
experiment. 
The lungs were harvested as described above and randomized, in blocks of four, to 
haemoconcentration by haemofiltration (HF) of the EVLP perfusate (n=7, HF group), 
or no haemofiltration (n=7, control group), during EVLP reconditioning. 
 
Haemofiltration during EVLP (paper I) 
 
A schematic overview of the EVLP circuit is found in Figure 3. Settings during different 
phases of the experiment are found in Table 2. 
Perfusate: EVLP was performed with the Vivoline LS1 EVLP system (Vivoline Medical 
AB, Lund, Sweden) (Figure 4). The system was primed with 2 l of Steen Solution (Vitrolife 
AB, Gothenburg, Sweden) and mixed with salvaged and washed red cells from the pig to 
a haematocrit of 10-15%. Imipenem, 500 mg (Meronem, AstraZeneca, Södertälje, 
Sweden), 10000 IU Heparin (LEO Pharmaceutical Products Ballerup, Copenhagen, 
Denmark) and methylprednisolone 1 g (Pfizer AB, Sollentuna, Sweden) were also added 
to the perfusate. The pH of the solution, measured after 10 minutes of circulation in the 
system, was corrected for every unit below zero in base excess with 1 ml of isotonic 
Figure 3. 
A schematic drawing of the typical EVLP unit with 
the option of haemofiltration of the perfusate.  
PA (pulmonary artery), LA (left atrium), HCU 
(heater/cooler unit). 
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trometamol plus an additional 5 ml empirically needed to achieve a pH of 7.35-7.45. After 
an additional 10 minutes of perfusion, the pH was measured again, and additional 
trometamol was added if needed.  
Perfusion: The lungs were prepared for EVLP with a custom-fitted cannula in the main 
pulmonary artery and a tube in the trachea; both secured in place with cable ties and 
connected to the outflow line from the EVLP unit and the ventilator (Figure 5).  The 
remnant of the left atrium was opened widely to prevent pulmonary vein outflow 
obstruction. A temperature probe was sutured inside the left atrium. PA-pressure was 
measured continuously with a catheter in the main pulmonary artery and was calibrated 
to zero to the bottom of the lung evaluation box. Pressure, as well as flow, could be 
regulated, and the perfusate temperature set to a specified degree, with a maximum 
temperature difference between lung in- and outflow perfusate not allowed to exceed 8°C 
during warming.  
The Vivoline LS1 is automated and has one phase for lung reconditioning and one for 
evaluation of lung function. During reconditioning, the oxygenator is supplied with a gas 
mixture of nitrogen 74%, oxygen 21% and carbon dioxide 5%. During the evaluation 
phase (see below), the oxygen supply is disconnected, and the oxygenator is used to 
deoxygenate the perfusate in the EVLP system with a gas mixture of 93% nitrogen and 
7% carbon dioxide. Flow during the reconditioning phase was set to a maximum of 40 
ml/kg/min and a minimum of 20 ml/kg/min. 
Figure 4. 
The Vivoline LS1 during ex vivo lung perfusion, together with the ventilator at the left of the picture.   
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Rewarming: When attached to the outflow cannula and the ventilator, having the 
temperature probe attached, perfusion was initiated in reconditioning mode and the 
temperature set to 15°C with the pulmonary artery pressure set to a maximum of 15 
mmHg and the maximum flow to 2-4 ml/kg BW/min. The shunt from the inflow cannula 
was closed after assuring that the perfusate was completely de-aired. Once the shunt was 
closed the temperature was set for 36°C, and the maximum flow increased to 4-8 ml/kg 
BW/min. This was maintained until 32°C was reached, when the maximum flow was 
increased to 6-12 ml/kg BW/min and pressure controlled ventilation was initiated, with 
a peak inspiratory pressure of 12 mmHg, PEEP 5 mmHg, a frequency of 7/min and a 
FIO2 of 0.5. At 34 °C, the maximum flow was increased to 10-20 ml/kg BW/min. 
First lung evaluation: When 36 °C was reached the lungs were recruited at a pulmonary 
perfusate flow of 0, with a PEEP of 15 mmHg. The ventilation was then set to a tidal 
volume of 6 ml/kg BW, a respiratory frequency of 10/min, a PEEP of 5 cm H2O and a 
FiO2 of 0.5. The system was set in evaluation mode, and the lungs were perfused with 
either a maximum PA pressure of 25 mmHg or a maximum flow of 6 l/min (the 
maximum flow of the pump). After 5 and 10 minutes, blood gases were drawn from the 
left atrium (outflow) and after the gas exchanger (inflow). Haemodynamic and respiratory 
variables were recorded. In addition, oncotic pressure of the perfusate was measured at 
five minutes after the start of the evaluation phase (Osmomat 050 Colloid Osmometer®, 
Gonotec GmbH, Berlin, Germany). 
Figure 5. 
Porcine lungs during EVLP. The cannula to the PA 
is seen in the centre of the image. The tube to the 
trachea is at the top of the image. 
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Reconditioning with/without haemofiltration: After the first evaluation, the system was again set 
in reconditioning mode with a perfusate flow of 20-40 ml/kg/min and a maximal PA 
pressure of 25 mmHg. Ventilation was continued with a tidal volume of 6 ml/kg body 
weight at a PEEP of 5 cm H2O and a respiratory frequency adjusted to obtain a minute 
ventilation 1.5 times the pulmonary artery flow. A haemofilter (Hemocor HPH 400; 
Medivators, Minneapolis, Minnesota) was attached to the circuit in seven EVLP circuits 
after randomisation (HF-group), with the aim of a total ultrafiltrate volume of 500 ml. 
The reconditioning phase continued for a total of 180 minutes. The lungs were recruited 
at a PEEP of 15 cm H2O every 60 minutes. Blood gases were drawn from left atrium and 
from the gas exchanger every 60 minutes and 1 ml of isotonic trometamol was given for 
every unit below zero in base excess. 
 
Table 2 – Settings during the different phases of the EVLP procedure. 
1 The EVLP device has one phase for reconditioning (oxygenator gas flow: nitrogen 74%, oxygen 21% and 
carbon dioxide 5%) and one for evaluation (oxygenator gas flow: nitrogen 93% and 7% carbon dioxide). 
2 Flow was restricted at different levels according to the stage of experiment. During evaluation flow limits were 
set to the maximum of the EVLP device, 6 l/min.  
FiO2 = fraction of inspired oxygen, PEEP = positive end-expiratory pressure, Vt = tidal volume, MV = respiratory 
minute volume, PA =pulmonary artery, PC = pressure-controlled ventilation, VC = volume-controlled ventilation, 
BW = body weight, Recond = reconditioning, f = frequency. 
 
Second lung evaluation: After 180 minutes, the system was again set in evaluation mode with 
the same flow and respiratory settings as during the first evaluation. Perfusate samples 
were taken, and recordings of haemodynamic and ventilatory variables were performed 
as described above. A bolus dose of nitroglycerine (15 mg) was administered to the 
perfusate at the end of the experimental procedure, followed by new measurements of 
haemodynamic and respiratory variables five minutes later. The lungs were then 
disconnected, the main pulmonary artery cannula and the tracheal tube were removed, 
and the lungs were weighed. 
Stage of experiment Rewarming  
1st 
evaluation 
Re-
conditioning 
2nd 
evaluation 
  -32°C  32-34°C  34-36°C        
EVLP device phase1 Recond Recond Recond Evaluation Recond Evaluation 
PA pressure 15 15 15 25 25 25 
PA flow range2  
(ml/kg BW/min)  
4-8 6-12 10-20 max 6 l/min 20-40 max 6 l/min 
Ventilation  
(FiO2 0.5, PEEP 5) 
      
     Mode - PC  VC VC VC VC 
     PIP / Vt - 12 mmHg 12 mmHg 6 ml/kg BW 6 ml/kg BW 6 ml/kg BW 
     f - 7 /min 7 /min 10 /min Adjusted to 
obtain 
10 /min 
     
MV 1.5 x PA 
flow 
 
Lung recruitment 
(PEEP 15 mmHg) 
      At start of 
evaluation 
Every 60 
minutes 
At start of 
evaluation 
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EVLP protocol comparison (paper II) 
 
Two experiments, one in each arm of the study, were performed each day in parallel. The 
animals each day were randomized to either the ACA group (n=10) or the COA group 
(n=10).  
The animals were exsanguinated to a cell saver as described previously (COA group) or 
to waste (ACA group). The lungs were then harvested as described above, with the 
following addition after retrograde perfusion: Tissue samples were taken from the inferior 
parts of the basal lobe of either the left or right lung in a randomized fashion. From this 
tissue, samples were secured for quantitative PCR (qPCR) and quantification of reactive 
Figure 6. 
(A) Experimental protocol for EVLP, (B) Rewarming protocol for the COA group,  
(C) Rewarming protocol for the ACA group. 
bw = bodyweight; FiO2 = fraction of inspired oxygen; PEEP, positive end-expiratory pressure; PIP, peak 
inspiratory pressure. 
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oxygen species (ROS) in tissue. The lungs were again weighed and stored in cold Perfadex 
at 8°C for two hours. After additional retrograde perfusion with 1 litre of Perfadex, 
preparations for EVLP were done according to the respective protocols, described below. 
An overview of the experimental protocol and rewarming strategies for the respective 
protocol is found in Figure 6. 
At the end of EVLP the lungs were again weighed, and tissue samples were secured for 
wet-dry weight ratio, qPCR, quantification of ROS and histopathological analysis.  
A collapse-test was performed in conjunction with the disconnection of the tracheal tube. 
Lung collapse was classified, subjectively, as normal or impaired, by one of the authors 
(TN) in all cases.  
The accessory lobe was selectively cannulated and perfused with a solution containing 
tryphan blue, followed by a formaldehyde fixative. A tissue sample was then taken from 
the accessory lobe and sent for histological analysis.  
Ex vivo lung perfusion – COA group  
 
Priming: EVLP was performed with the Vivoline LS1 system primed with 1.5 l of Steen 
solution and added salvaged red blood cells to a haematocrit of 10-15%, 
methylprednisolone, and heparin as described above for paper I.  
Perfusion: The lungs were prepared and connected to the EVLP device. After de-airing of 
the circuit, the lungs were rewarmed to 37°C. Pulmonary flow was allowed to increase 
gradually as temperature increased to a target of 40 ml/kg BW. Ventilation was initiated 
at 32°C. When 36°C was reached a lung recruitment manoeuvre was performed and FiO2 
set to 1.0. At 60 minutes after initiation of EVLP the first evaluation was performed, with 
evaluation performed in evaluation mode. A reconditioning phase of 240 minutes then 
followed. The lungs were recruited every 60 minutes during temporary arrest of 
perfusion176 and arterial blood gases (ABG) were drawn after a period of stabilization 
from the recruitment manoeuvre. Base excess was corrected with 1 ml of trometamol for 
every unit below zero. After 240 minutes of reconditioning, the lungs were recruited and 
FiO2 set to 1.0. Five minutes later a second evaluation was performed. During both 
evaluation phases, the lungs were perfused at a constant flow of 40 ml/kg BW/min.  
Ex vivo lung perfusion – ACA group  
 
Priming: EVLP was performed with a custom-built system using disposables supplied by 
XVIVO (XVIVO AB, Gothenburg, Sweden) and a Cardiohelp System (Maquet, Getinge 
Group, Sweden) used for perfusion (Figure 7). The system was primed with 1.5 l of Steen 
solution, methylprednisolone, and heparin.  
Perfusion: The lungs were prepared and connected to the EVLP device, ensuring adequate 
de-airing of the perfusate. The left atrium was cannulated, and LAP was continuously 
maintained at 5 mmHg during EVLP. The lungs were then rewarmed to 37°C, with a 
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pulmonary flow (Qp) allowed to increase gradually, as temperature increased, to a target 
of 40 ml/kg BW/min. Ventilation was initiated at 32°C. When 37°C was reached, a lung 
recruitment manoeuvre was performed and FiO2 set to 1.0. Sixty minutes after initiation 
of EVLP, the first evaluation was performed. 400 ml of the perfusate was then exchanged 
for fresh Steen solution followed by a reconditioning phase of 240 minutes. 200 ml of 
perfusate was exchanged for new Steen solution at 60, 120 and 180 minutes. The lungs 
were recruited every 60 minutes during temporary arrest of perfusion and perfusate 
samples for blood gas analysis were drawn. At 240 minutes of reconditioning, the lungs 
were recruited and FiO2 set to 1.0. Five minutes later the second evaluation followed. 
During both evaluation phases, the lungs were perfused at a constant flow of 40 ml/kg 
BW/min. 
Quantification of reactive oxygen species in tissue (paper II) 
 
In collaboration with the Laboratory for Microbiology, Parasitology and Hygiene, 
Antwerp University, Antwerp, Belgium, electron spin resonance (ESR) was used for the 
detection of free radical formation generated during EVLP in lung tissue. Vitamin C was 
used as an endogenous spin probe with a high sensitivity and specificity for intracellular 
ROS. Snap frozen samples of pig lung were briefly thawed and homogenized (Qiagen 
TissueRuptor, Qiagen, The Netherlands). Homogenates were placed on ice for direct 
measurements using ESR spectroscopy. 60 µL of homogenate was loaded into a quartz 
glass capillary (Duran Rincaps, Hirschmann, Germany) to acquire the ESR spectrum 
using a table top MiniScope MS 200 spectrometer (Magnettech, Germany). Results were 
recorded using Analysis 2.0 (Magnettech, Germany) software and expressed as ESR peak 
Figure 7. 
Porcine lungs during EVLP in the ACA group. The 
cannula to the PA and the cannula for the return of 
pulmonary venous blood are seen in the centre of 
the image. The tube to the trachea is at the right of 
the image. 
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amplitude arbitrary units (A.U.) as a measure of free radical concentration in the observed 
sample.  
Tissue gene expression (paper II) 
 
Tissue from lungs was harvested at two time points, before and after 4 hours of EVLP. 
Tissue samples were homogenized, and RNA was extracted using a Maxwell® 16 LEV 
simplyRNA Tissue kit (Promega, USA) on a Maxwell® 16 MDx Instrument (Promega, 
USA), according to manufacturer’s protocol, by the author.  
The Genomics Core Facility, at Gothenburg University, performed the remaining 
procedures: The RNA concentration and purity were measured using Nanodrop. The 
RNA quality was evaluated with Tapestation 2200 (Agilent Technologies, USA). cDNA 
synthesis was performed with a SuperScript® VILO™ cDNA Synthesis Kit (Life 
Technologies, Sweden) on a 2720 Thermal Cycler (Applied Biosystems, USA)  
Nanodrop II (GC Biotech, The Netherlands) was used to setup the qPCR plates. To run 
the qPCR, the QuantStudio™ 12K Flex Real-Time PCR System (Life Technologies, 
Sweden) instrument was used. TaqMan® Gene Expression Master Mix (Life 
Technologies, Sweden) and TaqMan® Gene Expression Assays (Life Technologies, 
Sweden), were used for detection of for IL-6, IL-8, IL-10, IL-1beta, TNF-alfa, IFN-
gamma, HIF-1alfa, and GAPDH. Everything was performed according to the 
manufacturer’s protocol and reaction volume was 5 µl.  
Histopathology (paper II) 
 
Tissue samples were taken for macroscopic examination, from the base of one of the 
lower lobes, and fixed in formaldehyde. They were embedded in paraffin, sectioned and 
stained with hematoxylin and eosin. A pathologist blinded to sample identity evaluated 
the sections with regards to vascular thrombosis, haemorrhage, necrosis, interstitial 
oedema, intra-alveolar oedema, intra-alveolar fibrin deposition, arteriolar thickening, cell 
infiltration, peribronchial oedema and cell infiltrate. The severity of these changes was 
graded as described by Inci et al177 and scored from 0 (absent) to 4 (severe). 
Tryphan blue staining to assess cell viability (paper II) 
 
Tissue from the accessory lobe perfused with tryphan blue and formaldehyde solution 
was fixed in formaldehyde solution. Samples were embedded in paraffin, sectioned and 
stained with eosin. Examination was performed as reported by D’Armini et al.178 Viable 
cell nuclei colours pink, non-viable as blue. The ratio of viable to non-viable nuclei was 
reported. 
Clinical Studies (Papers III and IV) 
 
Patients from Copenhagen and Gothenburg were prospectively and consecutively 
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included between January 2011 and December 2015, and followed until the end of 
December 2016. DBD donors primarily rejected for transplantation were considered for 
EVLP. Lungs that, during EVLP, achieved acceptable lung function were transplanted.  
Surgery was performed as to local preference and routine, either via bilateral sequential 
thoracotomy or sternotomy, either with or without extracorporeal circulation. Outcome 
in recipients transplanted after EVLP or without prior EVLP were compared (Paper III), 
with regards to short-term outcome expressed as PaO2/FiO2 at arrival in ICU, time on 
ventilator, time in ICU, time to discharge and survival. Medium-term outcome expressed 
as lung function at one year and survival free from re-transplantation was also studied.  
Ventilator time was defined as time to extubation in hours. Time in ICU was defined as 
the number of days from ICU arrival to general ward discharge. If the recipient was re-
intubated during the index procedure hospitalization, ventilator time was defined as the 
total ventilator treatment time. 
Correlations between factors during EVLP and short-term outcome were studied in lungs 
that were transplanted (Paper IV). Univariate and multivariate linear regression was 
performed on the seven prognostic variables and the three outcome variables. 
Clinical EVLP  
 
EVLP at our two centres was performed based on a modified version of the procedure 
described by Stig Steen et al.,49 and has been extensively described by Wallinder et 
al.1,60,74,75 Equivalent protocols were applied in both institutions, using the Vivoline LS1 
device, perfused with Steen solution mixed with red blood cells to a haematocrit of 10-
15%, 10000 U of heparin and 100 mg of meropenem. Following lung recruitment 
manoeuvres and bronchoscopy, evaluation was performed at 36 degrees C, at full 
perfusate flow and pressure.  
Acceptable lung function was defined as: a) PaO2/FiO2 ratio >40 kPa (Gothenburg) 
PaO2/FiO2 >50 kPa at FiO2 1.0 or Pao2 >13 kPa at FiO2 0.21 (Copenhagen). b) 
pulmonary vascular resistance (PVR) and pulmonary compliance deemed normal and not 
deteriorating during EVLP; c) macroscopic appearance and manual inspection without 
major pathology. 
Physiological dead space fraction, static lung compliance and PVR were continuously 
monitored. A collapse test was performed to evaluate the compliant properties of the 
lungs and was graded as normal or impaired.  
Accepted lungs were surface cooled in the EVLP system awaiting transplantation. 
Following transplantation patients received care according to local standard practice and 
protocol. 
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Statistics 
 
A p-value of <0.05 was considered statistically significant. Inspection of normal Q-Q 
Plots and the Shapiro-Wilks test were used for testing continuous variables for normal 
distribution. Statistical analysis was performed using IBM SPSS Statistics for Macintosh, 
Version 22 and 23 (IBM Corp., Armonk, NY). 
Experimental animal studies (papers I and II) 
 
Continuous data were presented as mean and standard deviation. Changes within groups 
were assessed by Wilcoxon’s signed-rank test. The relative changes of the variables 
between groups were compared using the Mann-Whitney U test. Correlations between 
variables were evaluated using the Pearson correlation coefficient. 
Short- and medium-term outcome after EVLP (paper III) 
 
Continuous data were presented as mean and standard deviation when normally 
distributed, otherwise as median and range. Categorical data were presented as frequency 
and/or percentage. Differences between groups were evaluated with the Student’s T-test 
in normally distributed data, otherwise with the Mann-Whitney U-test. Kaplan-Meier 
curves were used for survival analysis and a log-rank test for comparison of proportional 
survival between the groups.  
Correlation of physiological variables during EVLP with short-term outcome 
post transplantation (paper IV) 
 
Continuous data were presented as mean and standard deviation and as median and range. 
Correlations between variables were evaluated using the Spearman's rank correlation 
coefficient. Univariate and multivariate linear regression was performed on the seven 
prognostic variables and the three outcome variables. 
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RESULTS 
 
 
Animal studies (papers I and II) 
 
Induction of pulmonary oedema (paper I) 
 
Two animals were excluded due to the inability to maintain study targets during induction 
of lung oedema.  
The HF and noHF groups did not significantly differ in body weight or body surface area. 
Induction of pulmonary oedema caused a decrease in oxygen saturation, arterial PO2, 
PO2/FiO2 ratio and compliance, an increase in arterial PCO2 and PVRI. The model was 
successful in inducing a pulmonary oedema. Lung weight after oedema induction was 
43% higher in the study group compared to the sham group of six animals (Figure 8). 
No significant differences were found between the noHF and the HF groups at the end 
of oedema induction with respect to oxygen saturation, arterial PO2, arterial PCO2, left 
atrial PO2/FiO2 ratio, compliance, dead space ratio or PVRI. The same applies to lung 
weight, lung weight/kg body weight, and lung weight/body surface area. 
At first evaluation, compared with in vivo values after pulmonary oedema induction, the 
left atrial PO2/FIO2 ratio increased considerably during EVLP whereas dead space ratio 
did not change significantly (Figure 9). 
Figure 8 
Lung weights after oedema induction in the 
two study groups, and the sham group. 
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Haemofiltration during EVLP (paper I) 
 
Haemofiltration during the reconditioning phase significantly increased the oncotic 
pressure of the perfusate by 43% and the haematocrit by 26%, whereas in the noHF 
group, there was only a minor increase in oncotic pressure (11%) and the haematocrit was 
unchanged. Haemofiltration caused a significant decrease of 15% in lung weight; lung 
weights were unchanged in the noHF group. 
Lung compliance decreased significantly in both groups during reconditioning, but 
significantly more so in the HF group. Changes in ΔPO2/FiO2 ratio, left atrial PO2/FIO2 
ratio, shunt fraction, arterial oxygen saturation and dead space during EVLP did not differ 
between groups. Both groups had a 55% decrease in pulmonary flow index, and a 2.3-to 
2.7-fold increase in PVRI, with no significant difference between groups. 
All lungs developed consolidation of the inferior lobes and an impaired collapse test.  
A close correlation was found, of both left atrial PO2/FIO2 and ΔPO2/FIO2 with 
intrapulmonary shunt fraction (r=0.71 and r=0.78, respectively). 
Nitroglycerine decreased PVRI in the nonHF and HF groups, by 45% and 35%, 
respectively, and increased pulmonary flow by 88% and 82%, respectively. Nitroglycerine 
impaired lung oxygenation capacity, as demonstrated by a decrease in the PaO2/FIO2 
ratio in both groups, as well as a decrease in ΔPO2/FIO2 in both groups. With 
nitroglycerine, intrapulmonary shunt fraction increased by more than half in both groups. 
EVLP protocol comparison (paper II) 
 
There were no differences in BW between the two study groups. In three lungs of the 
ACA group, severe oedema developed during EVLP. The perfusate volume reached such 
low levels in these three cases that it was not possible to continue EVLP reconditioning 
as planned. The second evaluation in these cases was therefore not possible to conduct, 
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Figure 9. 
PaO2/FiO2 at different stages of the 
experiment in paper I. 
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and statistics are based on the seven cases in the ACA group in which the protocol could 
be finalized. EVLP of the lungs in the COA group was performed as planned in all 
experiments (n=10). Mean lung weights increased significantly in both groups during 
EVLP. There was a trend for a more pronounced increase in the ACA (44%) compared 
to the COA group (23%, p=0.065).  
The transpulmonary oxygen gradient decreased significantly in the ACA group but not in 
the COA group (Fig. 10). The dead space fraction increased in the ACA but not in the 
COA group. Compliance decreased significantly in both groups, by 44% in the ACA 
group, and by 25% in the COA group with a trend for a more pronounced decrease in 
the ACA group (p=0.083). PVRI increased significantly in both groups. This increase in 
PVRI did not differ between groups. The oncotic pressure increased in both groups 
during EVLP. This increase was significantly more pronounced in the COA group (20%) 
compared to the ACA group (9%, p = 0.001). All lungs in both groups developed 
consolidation of the inferior lobes and exhibited an impaired collapse test.  
Quantification of reactive oxygen species in lung tissue (paper II) 
 
We could not observe any significant difference between groups in changes in peak-to-
peak amplitude measurements of pulmonary ascorbyl radical signal in lung tissue, from 
the first to the second evaluation (p=0.436). Electron spin resonance peak amplitudes 
(arbitrary units) were 1,070 ± 234 before and 965 ± 247 after EVLP in the ACA group 
(p=0.475) compared with 917 ± 123 before and 966 ± 257 after EVLP in the COA group 
(p=0.878). 
Tissue gene expression (paper II) 
 
The expression of hypoxia-inducible factor (HIF)-1alpha decreased significantly in both 
groups during EVLP with no difference between groups. The levels of the mRNAs for 
the proinflammatory cytokines IL-6 and IL-8 decreased to similar extent in both groups, 
while TNF-alpha decreased in the ACA group and increased in the COA group 
(p=0.003). The level of the mRNA for the anti-inflammatory cytokine IL-10 decreased in 
the ACA group but not in the COA group (p=0.005)   
Histopathology (paper II) 
 
Histologic examination showed mild pathology in a few cases. Mild interstitial infiltrates 
were noted in two samples in each group. Mild arteriolar thickening was present in two 
samples respectively in each group. There was no apparent difference in lung 
histopathology between groups and no relevant statistical analysis could be performed.  
Tryphan blue staining to assess cell viability (paper II) 
 
There was no statistically significant difference between the groups with regards to the 
viable/non-viable nuclei ratio.  
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Figure 10. 
Mean values of lung weight/kg body weight, transpulmonary oxygen gradient, compliance, pulmonary 
vascular resistance index, dead space fraction and perfusate oncotic pressure before and after four 
hours of EVLP reconditioning. P-values indicate difference in change between groups. p < 0.05 is 
considered significant. 
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Clinical studies (papers III and IV) 
 
Short- and medium-term outcome after EVLP compared to conventional lungs 
(paper III) 
 
During the four-year study period, from January 2011 to December 2015, with 
Gothenburg initiating its clinical EVLP program in January 2011 and Copenhagen in May 
2012, lungs from 1013 donors were offered to our two centres, and 54 patients underwent 
lung transplantation with initially rejected lungs but subsequently used after EVLP. All 
other contemporary lung transplantation (n=271) procedures with organs accepted 
according to standard selection criteria not requiring EVLP, were included as a control 
group. Re-transplantations during the study period were excluded. Recipient 
characteristics between groups were similar, including age of recipients and diagnosis 
underlying the indication for transplantation. A higher percentage of recipients in the 
EVLP group were on preoperative ventilatory support, while in the control group a higher 
percentage were on preoperative ECMO (Table 3). 
In our combined cohort, 61 donor lungs underwent EVLP. Forty-seven double lungs 
were deemed transplantable. In one of these cases the pair of lungs were split and 
transplanted in two different recipients. In one case bilateral bilobar transplantation was 
performed. In five cases, one of the lungs was used for singe lung transplantation, and 
the other discarded after EVLP. This results in a conversion rate of 87% (53/61) of all 
EVLP cases. 246 double lung transplantations and 37 single lung transplantations were 
included in the control group. The use of intraoperative ECC/ECMO was similar in the 
two groups.  
Table 3 - Recipient characteristics  
V.      
Recipient variable   EVLP Conventional 
Age (years)  52 ± 12 51 ± 13 
Diagnosis (%)    
VI.  IPF  24 25 
VII.  PAH  2 6 
VIII.  COPD  33 28 
IX.  Alfa-1-antitrypsin deficiency 6 13 
X.  CF  20 12 
XI.  Other  15 16 
Preoperative ventilator 5 (9.3 %) 12 (4.4 %) 
Preoperative ECMO 1 (1.9 %) 16 (5.9 %) 
XII.  XIII.     
 
IPF = interstitial pulmonary fibrosis, PAH = pulmonary artery hypertension, 
COPD = chronic obstructive pulmonary disease, CF = cystic fibrosis, ECMO 
= extracorporeal membrane oxygenation. 
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One patient in the EVLP group and four in the conventional group died within the first 
48 hours after transplantation. In none of these cases was death attributable to insufficient 
lung function. PaO2/FiO2 at arrival in ICU was significantly lower in the EVLP group, as 
were time to extubation and median ICU-stay. Time to discharge to home or 
rehabilitation did not differ between groups (Table 4).   
One-year survival, free from re-transplantation, was 87% (95% CI 82-92%) in the EVLP 
group and 83% (95% CI 81-85 %) in the conventional group. Cumulative survival, free 
from re-transplantation during the entire period did, in our combined cohorts, not differ 
significantly between the groups (Figure 11). 
Lung function tests did not show a significant difference in FEV1% at one year after 
transplantation (Table 4).   
 
Correlation of physiological variables during EVLP with short-term outcome 
after transplantation (paper IV) 
 
During the study period 54 patients received lungs that had undergone EVLP prior to 
transplantation. In 46 cases both lungs were transplanted, in one case a bi-lobar 
transplantation was performed and in 7 cases single lung transplantation was performed.  
Table 4 - Intra- and postoperative characteristics  
XIV.  XV.  XVI.    
Variable   EVLP Control p-value 
Number of patients 54 271  
   Single LTx XVII.  7 (13%) 37 14%)  
   Double LTx XVIII.  47 (87%) 234 (86%)  
Intraoperative ECC/ECMO 29 (54%) 125 (46%)  
PaO2/FiO2 at arrival in ICU 
(kPa) 30 ± 14 36 ± 14 0.005 
Time to extubation (hours) XIX.  XX.   
  (median and range) 18 (2-912) 7 (0-2280) 0.002 
ICU stay (days)  XXI.  XXII.   
  (median and range) 4 (2-65) 3 (1-156) 0.002 
Time to discharge (days) XXIII.  XXIV.   
  (median and range) 30 (17-112) 28 (12-268) 0.35 
FEV1% at 12 months 75 ± 29 81 ± 26 0.18 
One-year survival 87% (CI 82-92%) 83% (CI 81-85%)  
          
LTx = lung transplantation, ECC = extra corporeal circulation, ECMO = extra corporeal membrane 
oxygenation, ICU = intensive care unit. FEV1% = forced expiratory ventilation in the first 
second/predicted. PaO2/FiO2 = arterial oxygen tension/inspired oxygen fraction. 
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In those patients receiving bilateral lung transplantation, correlations between commonly 
recorded variables and physiologic parameters during EVLP, and clinical outcome, were 
tested for correlations against PaO2/FiO2 at arrival in ICU, recipient time to extubation 
and recipient time in ICU. No significant correlations were found. (Table 5).  There were 
no significant uni- or multivariate regression models that predicted poor outcome. 
   
 
 
Table 5 - Correlations between variables during EVLP and outcome measures
PaO2/FiO2 at arrival in ICU Recipient time to extubation Recipient time in ICU
rs p rs p rs p
PaO2/FiO2 (1.0) (kPa) at EVLP -0.060 0.708 -0.110 0.487 -0.052 0.741
Compliance (ml/cm H2O) 0.090 0.572 -0.279 0.074 -0.059 0.708
Dead space fraction -0.246 0.132 0.040 0.811 0.017 0.918
Pulmonary vascular resistance ([dynes x s]/cm5/m2) 0.041 0.793 -0.022 0.890 -0.112 0.469
Lung weight change (g) 0.257 0.137 -0.084 0.631 -0.087 0.616
Lung weight at end of EVLP (g) -0.181 0.297 -0.020 0.910 0.076 0.660
Duration of EVLP (hours) -0.109 0.486 -0.062 0.694 -0.088 0.571
PaO2 = partial pressure of oxygen in arterial blood; FiO2 = fraction of oxygen in inspired air; EVLP = ex vivo lung perfusion; 
ICU = intensive care unit; PFD = P/F difference
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DISCUSSION 
 
 
Ex vivo lung perfusion has during the last decade firmly been established at a wide range 
of transplantation centres around the globe as a method of evaluating marginal organs 
and increasing numbers of transplantable organs. This thesis deals with both experimental 
and clinical aspects of EVLP.  
In the first experimental study (paper I), pulmonary oedema was successfully induced 
using left atrial outflow obstruction and crystalloid loading. Haemofiltration during EVLP 
was established as a method of increasing the oedema reducing properties of EVLP, as 
previous clinical experience had shown that lungs may both gain and lose weight during 
standard EVLP.60 Adding a haemofilter to the circuit and filtrating the perfusate could 
uphold oncotic pressures, promoting clearance of tissue oedema.  
In paper II, a comparison was made between the two prevailing methods for EVLP, the 
Lund and the Toronto protocol, as they are clinically adapted and performed in 
Gothenburg and Vienna respectively.1,87 The original method, the Lund protocol has been 
superseded by the Toronto protocol in numbers of performed clinical EVLP:s.65 Previous 
studies have reported on comparisons on specific differences between the protocols, such 
as acellular to cellular perfusate.68 However, in this study, the two protocols were 
compared head-to-head the way they are clinically performed, in the setting of a standard 
EVLP evaluation, with a time frame of four hours. Lung edema formation and decreased 
lung compliance occurred with both EVLP techniques but were more pronounced in the 
ACA group. Otherwise, there were no differences in lung function, inflammatory 
response, ischemia/reperfusion injury, or histopathological changes between the EVLP 
techniques. A novel method in the porcine setting of evaluating cell viability using tryphan 
blue staining was introduced. 
Short-term outcome after EVLP has been widely published, although medium- and long-
time follow up is scarcer. A thorough account of publicised clinical results has been made 
in the introductory chapter. Paper III reports on short- and medium-term outcome after 
EVLP compared to a contemporary control group, in collaboration between Sahlgrenska 
University Hospital, Gothenburg, Sweden, and Rigshospitalet in Copenhagen, Denmark. 
Although short-term outcome differs with respect to time on ventilator and time in ICU, 
the groups showed similar results in lung function at one year as well as survival, free 
from re-transplantation. The material is one of the larger published to date and the most 
comprehensive using the Lund protocol.  
EVLP evaluation and the final decision to accept organs for transplantation is a synthesis 
of a wide range of variables and factors. In addition to physiological variables such as 
PaO2/FiO2, compliance and PVR and their dynamics during EVLP, the touch, feel and 
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look of the organs, as well as the history of the donor are integrated into the decision to 
proceed with transplantation. Paper IV searched for factors during EVLP that could 
predict short-term outcome in the patient, however there was no clear correlation 
between commonly registered variables during EVLP and early clinical outcome. 
Ethical considerations 
 
The relevant Regional Ethical Review Boards approved all experimental and clinical 
studies.  
A prerequisite for the ethical acceptability of performing animal studies for scientific 
purposes is that the expected value of gained information from the experiments 
outweighs any potential suffering of the animals, and that relevant information cannot be 
gained in other ways, in vitro, or in human studies. Into account must also be taken the 
fact that the results of animal experimental studies often cannot be directly extrapolated 
to human clinical conditions, and that there is often a discordance between animal studies 
and clinical trials.179 The two animal experimental studies of this thesis could not have 
been performed on human lungs, due to the lack of suitable human organs, or in vitro. 
The principle of the 3Rs (replace, reduce, refine) in animal scientific experiments was 
adhered to in the planning and setting up of the experimental protocols.  
All animals received care in compliance with the European Convention for the Protection 
of Vertebrate Animals Used for Experimental and Other Scientific Purposes (1986), the 
Principles of Laboratory Animal Care formulated by the National Society for Medical 
Research, and the Guide for the Care and Use of Laboratory Animals from the National 
Institutes of Health.  
A veterinarian supervised animal handling and care before and during the experimental 
procedures. The animals were professionally handled with care and respect by all involved 
personnel, unnecessary discomfort and suffering minimized, thereby optimizing 
conditions for reproducible experimental results and minimizing unnecessary loss of 
animals. All animals were euthanized by exsanguination under general anaesthesia. 
In the clinical studies (papers III and IV) all patients were informed and gave oral and 
written consent, when listed for transplantation, to the possibility of receiving organs that 
had undergone EVLP. The organs were otherwise matched according to standard criteria. 
The patients could unconditionally withdraw from the studies at any time.  
Experimental studies (paper I and II) 
 
Lung oedema model (paper I) 
 
The model of inducing oedema by means of left atrial outflow obstruction and crystalloid 
infusion was successful. Compared to a sham group of six animals, where lungs were 
harvested without prior oedema induction and weighed prior to EVLP, lungs subjected 
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to oedema induction weighed 43% more, corresponding to a gained oedema volume of 
about 300 ml. The model was stable and predictable, however care had to be taken to 
gradually increase the left atrial outflow obstruction and PCWP, else the animals were 
susceptible to the development of right heart failure, which, once established, proved to 
be very difficult to manage. Two animals were excluded for this reason.  
Reduction of pulmonary oedema by haemofiltration during EVLP (paper I) 
 
Haemofiltration during EVLP, initially described by our group, significantly increased 
both perfusate oncotic pressure and haematocrit, increasing the forces promoting a fluid 
shift from perivascular and interstitial space to the vascular lumen. A significant decrease 
in lung weights after EVLP in the group subjected to haemofiltration indicate that up to 
a third of the induced oedema could be relieved. 
The non-significant increase in lung weight together with the small increase in oncotic 
pressure in the group without haemofiltration during EVLP indicate a fluid shift from 
perfusate to tissues, with the development of oedema during EVLP. This contradicts the 
perception of Steen Solution as having potent oedema-reducing properties. It also 
contradicts the practice of intermittently exchanging perfusate during EVLP, as practiced 
in the Toronto protocol, as this will decrease the overall oncotic pressure of the perfusate 
during the course of EVLP, and therefore increase the tendency of oedema development. 
Although the effect of haemofiltration on lung weight and hence oedema content was 
significant, this did not, in this study, translate into better lung performance expressed as 
PaO2/FiO2. Compliance decreased in both groups during EVLP, but more so in the non-
haemofiltration group. All lungs developed basal atelectasis and exhibited a pathological 
collapse test upon completion of EVLP. 
Impact of prolonged EVLP on haemodynamics and compliance  
 
In both experimental papers, across protocols, there was a tendency for PVR to gradually 
increase and compliance to decrease during EVLP. Uniformly there was development of 
basal atelectasis and a pathological collapse test, despite hourly lung recruitment 
manoeuvres during EVLP. Except for in the haemofiltration group of paper I, there was 
also a tendency for increased lung weights after EVLP, and hence increased pulmonary 
oedema. Most excessively so in the Toronto arm of paper II, where in three cases, EVLP 
had to be ended prematurely due to the development of excessive pulmonary oedema 
and lack of perfusate in the circuit. 
Although prolonged EVLP in porcine lungs has been described by Cypel et al, the same 
group in 2012 reported on the development of oedema during EVLP, decreased 
compliance and subsequently poor performance in vivo after transplantation, in porcine 
lungs transplanted after prolonged ischemia and 12 hours of EVLP.54,138  Pierre et al 
described increasing weight of lungs with increased time of EVLP, and could not show 
any improvement in lung grafts as a result of additional EVLP times.148  
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This tendency to develop oedema during EVLP, with deteriorating haemodynamics and 
compliance over time, is not uniformly seen during EVLP in human lungs where 
successful prolonged EVLP has been reported repeatedly using the Toronto and OCS 
protocol.163,180,181 The Gothenburg group reported that lungs may both gain and lose 
weight during clinical EVLP.60 Other research groups have in personal correspondence 
reported the same experiences in experimental setups applying porcine models. This 
difference in behaviour during EVLP has to be taken into account when planning and 
interpreting results in porcine lungs. However, porcine models for EVLP is established 
as one of the best parallels to humans. It is size appropriate with comparable respiratory 
and hemodynamic settings as in humans, making it possible to use the same technical 
equipment in experimental studies as in clinical practice. Also, the immune system and 
biology are similar to humans, and the availability and cost of animals is reasonable.  
Oedematous lungs are heavier due to additional fluid content. In the supine position, the 
degree of lung inflation at any point along the dorso-ventral axis is dependent on the 
weight of the tissue compressing it from above. The more oedematous the lungs are, the 
more prone they will be to development of basal atelectasis. In addition, in the context of 
EVLP there is no negative pleural pressure supporting the lungs. This tendency to 
develop basal atelectasis might be counteracted by a more active approach in keeping all 
lung tissue recruited, for example by using a higher level of PEEP, and, if it could be 
technically feasible during the process of EVLP, turning the lungs over to promote 
recruitment of alveoli and counteract any atelectatic tendency, in analogy with the clinical 
practice of ventilating patients in the prone position. 
PVR increased gradually over the course of EVLP, and this increase could be 
counteracted using a vasodilating agent, nitroglycerine. There may be several reasons for 
this tendency. It could partly be explained by a hypoxic pulmonary vasoconstrictive 
response to the development of poorly ventilated lung segments in conjunction with 
atelectasis. It could be hypothesized that the use of red blood cells in the perfusate may 
increase this response by the inactivation of nitric oxide by haemoglobin,182 and maybe 
also due to the release of free haemoglobin in the cell salvage procedure as a result of 
haemolysis. Free haemoglobin binds nitric oxide, which acts as an endogenous 
vasodilator, thereby inducing pulmonary vasoconstriction.183 However, in the comparison 
between acellular and cellular perfusates by Roman et al, there was no difference in PVR 
between groups.67 
PaO2/FiO2 for the evaluation of lung function 
 
The left atrial PaO2/FiO2 (PF) ratio has been extensively used as an indicator of lung 
function in patients with acute lung injury, and others. The PF-ratio is included as one of 
the parameters in the ISHLT definition of the ideal donor,26 and all EVLP protocols aim 
to achieve normal ratios during EVLP. In vivo, the ratio is affected by FiO2, 
intrapulmonary shunt fraction and mixed venous oxygen content.141 In both experimental 
studies, the transpulmonary oxygen gradient, ΔPaO2/FiO2 was reported. It is the 
difference in oxygen tension between the venous blood entering the lung and the 
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oxygenated blood leaving the lungs divided by the inspired oxygen fraction, with the 
intention of excluding the influence of any differences in mixed venous oxygen content 
entering the lung. In paper I, a close correlation between calculated shunt fraction and 
both ΔPaO2/FiO2 and PaO2/FiO2.were shown, indicating that both variables could be 
used to assess the degree of ventilation/perfusion mismatch, and hence the degree of lung 
injury. 
The Lund protocol adds red blood cells to the perfusate in contrast to the Toronto 
protocol, which uses acellular perfusate. Analyses of PaO2/FiO2 in acellular perfusate 
cannot reliably be used to assess lung function, especially in the presence of a large 
mismatch in ventilation/perfusion.138 Therefore, in Gothenburg, we continue to use 
cellular perfusate and evaluate at full flow. Roman et al. did not find any significant 
differences in physiologic, immunologic, or ultrastructural parameters in a porcine 
experimental study, comparing cellular to acellular perfusate.67 
 
Being a rather blunt tool, since PaO2/FiO2 is influenced by a variety of factors, and 
performing poor as an indicator of lung performance in EVLP using acellular perfusate, 
focus has shifted to other variables during EVLP, such as compliance.140,142,143,184 
However, all variables continue to add important information to the overall picture, and 
decision to go ahead with transplantation after EVLP is ultimately a synthesis of a number 
of factors. 
A novel parameter in the assessment of lung function during EVLP is the PF-difference. 
It is the difference between PaO2 at two different FiO2, and is dependent on shunt 
fraction, with decreasing PF difference with increasing shunt and hence poorer lung 
performance. Niikawa et al. will report on this parameter in an abstract to the 2018 ISHLT 
meeting as a variable for assessing transplant suitability in EVLP. Further studies will be 
needed to assess whether it is a useful addition and will find its way into clinical practice.  
Comparison of EVLP protocols (paper II) 
 
Although being the first protocol described, the Lund protocol has been challenged by 
the Toronto protocol, which now is the clinically most applied.185 Philosophies differ; the 
Lund protocol’s primary aim is evaluation, spending no more time than necessary on 
EVLP. The Toronto protocol has a different approach appreciating the therapeutical 
capabilities of EVLP, aiming for extension of EVLP times in order to give a specific 
treatment time to achieve its effect. Recent years research has been focused on EVLP as 
a means of extending the timeframe between donation and transplantation.96,181 In 
addition to these different views on the fundamental role of EVLP, the protocols differ 
with respect to the use of cellular or acellular perfusate, open or closed atrium, the kind 
of pump used in the circuit and the pressures and flows aimed for during EVLP.44,54  
In previous publications these differences have been studied from certain aspects, for 
example acellular versus cellular perfusate by Roman et al and Becker et al.67,68 The 
Toronto group has expressed belief in the importance of maintaining a positive LA 
pressure, using a specifically adapted catheter, by monitoring outflow pressures during 
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the EVLP procedures.86 Paper II in this thesis is the first head-to-head comparison of 
these two protocols in the setting of a normal EVLP-evaluation within a time frame of 
four hours. 
Our research group has substantial experience in performing EVLP according to the 
Lund protocol, being applied both in clinical practice, and used for experimental research. 
To ensure that the Toronto arm of paper II was executed correctly, we collaborated with 
a representative of the Vienna EVLP program in the planning and execution of the study 
protocol. To study ischemia/reperfusion injury and detect free radicals in tissue, we 
collaborated with a research group in Antwerp, Belgium, experienced in this field.186,187 
Taking into account the development of severe pulmonary oedema in three cases in the 
Toronto arm, biasing the results of the remaining seven cases, and the trends towards a 
more pronounced increase in lung weight and decrease in lung compliance, albeit not 
statistically significant, there was a tendency towards a more pronounced accumulation of 
oedema in the Toronto group. There was also a fall in oxygenation capacity, and an 
increase in dead space, in the Toronto group, but not in the Lund group. However, the 
differences between groups were not significant. 
Lung fluid accumulation during the EVLP process, with a fall in compliance and impaired 
oxygenation capacity could be explained by increased microvascular permeability caused 
by ischemia/reperfusion injury.186,188 Results in paper II are in line with those of paper I, 
and with clinical experience in Gothenburg,1 and has been reported by others.68,148 The 
same target pulmonary flow was achieved in both study groups and hence over-perfusion 
could not be blamed for oedema development. Perfusion with acellular perfusate could 
theoretically lead to progressive tissue hypoxia in the Toronto group due to the lack of 
red blood cells. Studies have shown hypoxia-inducible factor 1α (HIF-1α) to increase 
substantially during EVLP.149,150 However, during the course of EVLP, expression of 
HIF-1α decreased in both groups, contradicting this hypothesis. 
As a consequence of ischemia/reperfusion injury, immune cells generate ROS and 
proinflammatory cytokines, leading to increased vascular permeability and the 
development of pulmonary oedema.188 In this study there was no significant difference in 
tissue ROS content before and after EVLP, and the levels did not differ between EVLP 
techniques. The expression of the proinflammatory cytokines IL-6 and IL-8 were down-
regulated during EVLP, while expression of TNF-α was down-regulated in the Toronto 
arm, and up-regulated in the Lund arm. Anti-inflammatory cytokine IL-10 expression 
increased in the Lund arm and decreased in the Toronto arm. Taken together there is no 
support for the assumption that inflammation-induced vascular permeability could be 
blamed for the development of oedema in either group. 
There were no differences between groups with regards to histopathological findings. 
Although an established method in experimental research, the histopathological findings 
were sparse in view of significant pulmonary oedema development and atelectasis, and 
no significant differences in lung ultrastructure could be seen.  
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The introduction of tryphan blue staining of the accessory lobe via selective perfusion 
proved to be feasible, yielding interpretable histopathological material. To the authors 
knowledge, this is the first report of the application of this method in a porcine 
experimental setting, it has previously only been reported in rodents.178 There was no 
significant difference in cell viability between groups. 
As in paper I, perfusate oncotic pressure increased during EVLP, due to extravasation of 
fluid and the development of oedema. The practice in the Toronto arm of intermittently 
replacing part of the perfusate with fresh Steen Solution may actually reinforce the 
tendency of extravasation, not allowing the oncotic pressure of the perfusate to increase 
to the same extent. This could be one of the reasons for the development of excessive 
pulmonary oedema in the Toronto arm of the study. 
In the study from 2013, the Toronto group showed that a closed atrium, maintaining 5 
mmHg of outflow pressure, during EVLP led to less oedema.86 The assumption is that a 
continuous positive outflow pressure will lead to a beneficial distribution of perfusion 
away from dependent regions of the lungs. However, increasing outflow pressure with a 
constant inflow pressure, transmural gradients will increase in the ex vivo setting, leading 
to fluid extravasation. Although established as a part of the Toronto protocol, there is still 
a need for further research before any firm conclusions can be drawn about its superiority 
over the open atrium technique. 
Limitations 
 
In addition to the above-mentioned limitations regarding the extrapolation of results in 
animal studies into humans, and limitations regarding the chosen animal model, the 
experimental studies in this thesis are small in size. Into consideration has therefore to be 
taken the risk for type II error, falsely retaining the null hypothesis. Another limitation to 
both paper I and paper II is the fact that lung performance was only tested ex vivo, and 
not in vivo after transplantation. Transplantation in a porcine setup after EVLP has been 
described in several studies and is feasible, however it is very labour intensive and highly 
expensive.119,138 
A significant limitation to paper II is that in three cases in the Toronto arm EVLP had to 
be prematurely terminated due to excessive oedema development and lack of perfusate 
in the circuit. Therefore no data at the second evaluation phase were obtained from these 
lungs and bias the results of the remaining seven organs to a more favourable outcome, 
underestimating any differences between the two protocols.  
Clinical studies (papers III and IV) 
 
Outcome in patients transplanted after EVLP 
  
The main finding is that the cumulative survival free from re-transplantation, for up to 
five years was comparable between groups (paper III), in a study from two Scandinavian 
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centres comparing outcome in 54 patients transplanted with lungs after EVLP with a 
contemporary control group transplanted with conventional non-EVLP organs. In the 
EVLP group, PaO2/FiO2 at arrival in ICU was significantly lower, and times on ventilator 
and in ICU were significantly longer, however, time to discharge from hospital, lung 
function at one year and one-year survival (87% in the EVLP group vs 83% in the 
conventional group) did not differ between groups.  
The high conversion rate (87%, 54 transplantations out of 61 EVLP:s performed) 
together with good long-term outcome in the EVLP group indicate both that the selection 
process for which lungs to submit to EVLP was adequate, and that the selection of which 
lungs to transplant after EVLP was appropriate. In view of an in international 
comparison,23,97 high level of donor utilization (27% for conventional lungs), it could be 
assumed that the threshold for exposing lungs to EVLP is not too low, unnecessarily 
evaluating organs that could have been transplanted without prior EVLP. 
In comparison with previous publications on outcome after transplantation with lungs 
subjected to EVLP,57 our definition on which lungs to submit to EVLP is more strict, 
and our study group is more homogenous, including only lungs from DBD donors with 
clear contra-indications to conventional transplantation. 
Implementation of an EVLP program together with the application of marginal donor 
criteria may increase donor utilization to as much as 50%. Centres with an already high 
acceptance rate may still increase its utilization rate, however the largest potential lies in 
centres with the lowest utilization rates. 
The EVLP program at our two institutions has been previously thoroughly described.1,74 
It is based on the Lund Protocol,40 using a cellular perfusate with banked blood 
(haematocrit 10-15%), an open left atrium and evaluation at physiological pressures and 
flow, but with the adaptation of a more restrictive approach to pressure and flow during 
reconditioning. Decision to accept lungs for transplantation after EVLP is in part based 
on reaching specific targets in oxygenation capacity of the lungs, and stable hemodynamic 
and ventilatory parameters. Macroscopic appearance, the look and feel of the organs, and 
performance during a collapse test are vital parts of the decision. No study has so far 
presented a validated algorithm for which lungs to accept for transplantation following 
EVLP. 
In this study conversion rate was 87%. A high number, which is in agreement with 
previous studies,65 that may be indicating that we should be even more generous in 
accepting lungs for EVLP, increasing available organs even further. 
Although EVLP according to the Toronto protocol has gained widespread use, and the 
numbers of EVLP:s using that protocol has surpassed the Lund protocol, this study 
indicate that good long-term results can be achieved with the Lund protocol. This is in 
line with our appreciation of EVLP, used primarily as an evaluating and reconditioning 
tool, although acknowledging the therapeutical potential. Although, time spent on EVLP 
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is no longer than needed to make a solid decision on the appropriateness of accepting the 
organs for transplantation. 
Inferior short-term results, with a lower PaO2/FiO2 at arrival in ICU, longer time on 
ventilator and longer time in ICU is not a surprise, since only marginal organs were 
subjected to EVLP, indicating that the selection of organs was appropriate, and that 
organs were not inappropriately subjected to EVLP. However, since medium- to long-
term outcome did not differ between groups, this indicates that residual pathology in 
transplanted lungs after EVLP was of a reversible nature. 
Our times on EVLP are relatively short (median 175 min, range 76-577 minutes). 
Although it has been stated that EVLP may reduce oedema,54 our clinical experience is 
that any set of lungs may either loose or gain weight during EVLP.1,60 Following the 
publication of a case report on haemofiltration during EVLP,61 and paper I in this thesis 
studying this in an experimental setup, we use hemofiltration in clinical practice of all 
lungs that undergo EVLP. 
Outcome measures are dependent not only on the state of the organs accepted after 
EVLP but on a wide array of factors such as the patient pre-operative status, the diagnosis 
responsible for the respiratory failure constituting the indication for transplantation, pre- 
and post-operative use of extracorporeal life support, peri- and postoperative 
complications such as bleeding, infection and sepsis, and rejection. In paper III, the 
diagnosis underlying the indication for transplantation were similar between groups, 
COPD being the most common reason, followed by interstitial lung disease such as 
fibrosis, being the second most common in both groups, in line with international data.13 
Bronchiectatic disease, such as cystic fibrosis was more common in the EVLP group, and 
α-1-anti-trypsin deficiency was more prevalent in the conventional group. Into 
consideration has also be taken that preoperative mechanical ventilation was more 
prevalent in the EVLP group (9 vs. 4 %) while preoperative ECMO was more prevalent 
in the conventional group (2 vs. 6 %). 
Time to extubation was more than doubled in the EVLP group compared to control, with 
a median of 18 compared to 7 hours. The range is substantial, varying from 2 to 2280 
hours in the whole cohort. This difference between groups was highly significant. 
Although, in both groups, time to extubation was low in comparison with earlier 
publications, Toronto reporting a median time to extubation of 2 days (range 1 -101),57 
Aigner et al. reporting median time of 48 hours and Zych et al. reporting median times of 
214 hours.87,89 This is in line with the focus at our two centres on early extubation, to 
non-invasive ventilatory support if necessary, promoting early mobilisation of the patient, 
aiming to avoid complications related to invasive ventilation. 
Time in intensive care is also a multifactorial outcome measure, depending on the 
preoperative state of the patient. Any pre-operative extracorporeal support is an indicator 
of poor pre-operative status of the patient, most often leading to a more prolonged course 
in intensive care. Any intra- or postoperative complication, such as bleeding, 
48 
postoperative respiratory failure and ventilator-associated pneumonia or sepsis 
necessitating prolonged invasive ventilatory support may extend times spent in ICU 
substantially. This is reflected in paper III by the fact that although median stay is only 3 
days in the control group and 4 days in the EVLP group, range is between 1 and 156 days. 
Different indications and organisations for intensive care versus care in step-down or 
high-dependency units may make comparison between different studies troublesome. 
The results of paper III is well in line with other larger materials published, Cypel et al. 
reporting a median ICU stay of 4 days and Aigner et. al of 5.5 days.57,87 In all those studies 
there was a substantial range in ICU stay. 
Variables during EVLP predicting good organ function in the donor 
 
The decision to proceed with transplantation after EVLP is multifactorial, integrating 
knowledge about the donor, the static and dynamic performance of the lungs during 
EVLP with regards to blood gas analysis, vascular resistance and lung dynamics, as well 
as the touch, feel and look of the organs. No single factor universally singles out the good 
from the bad organs, and to date no validated protocol regarding which organs to accept 
has been presented. 
It could be assumed that the better the organs perform during EVLP, the better they will 
perform in vivo after transplantation. However, we could not in this study find any 
correlations between physiologic variables measured during EVLP and three commonly 
used outcome measures in the transplanted patient. It might be explained by selection 
bias, as only lungs regarded as suitable for transplantation were used, making numbers 
too small in this study to detect any correlations that actually exist. 
Although research is active in finding both novel physiological parameters better 
reflecting suitability for transplantation, such as the PF-difference, and biochemical 
markers for god transplant function, the decision process during EVLP will likely 
continue to be a synthesis of multiple factors. 
Limitations 
 
The clinical studies are retrospective studies based on prospectively collected data. 
Although the same EVLP protocol has been used at our two centres, minor differences 
exist in the selection processes and in the clinical perioperative management of patients. 
The surgical method also differs between centres, sequential bilateral thoracotomy 
without the use of ECC being favoured in Gothenburg, while the use of ECC and 
sternotomy is more prevalent in Copenhagen, during the study period.  
Although being one of the larger materials presented to date, numbers are still small, and 
conclusions from this non-randomized study cannot be compared with that of a 
randomized one. Numbers at risk at the far end of the survival analysis are small and care 
has to be taken in interpreting differences between groups. 
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There were missing registry data in certain variables, and although great efforts were made 
to make the data as complete as possible, this could possibly have influenced results.  
In paper IV, there has already been a selection process, in that only lungs accepted for 
transplantation are included in the analysis. They are all considered acceptable for 
transplantation, fulfilling criteria, and it could therefore be that numbers are too small in 
this study to detect any existing correlations between variables during EVLP and 
outcome. The outcome parameters, in addition, are affected not only by the status of the 
transplanted organ, but by the preoperative state of the recipient and any post-operative 
complications such as sepsis, pneumonia or rejection. 
In paper IV, quite a few parameters are investigated for correlations with the outcome 
parameters. Had there been positive correlations found, in the setting of analysing that 
many parameters, it might have been due to chance alone (type I error). 
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CONCLUSIONS 
 
 
In paper I, after induction of pulmonary oedema, haemofiltration during EVLP increased 
perfusate oncotic pressure, decreased lung weight, had beneficial effects on compliance 
and the potential to reduce pulmonary oedema content by as much as 50%. It did however 
not improve lung oxygenation capacity. 
EVLP alone, without haemofiltration, did not reduce the degree of pulmonary oedema in 
this model. Perfusate oncotic pressure increased during EVLP in the control group, 
contradicting the practice of intermittent perfusate exchange during EVLP. 
In the EVLP comparison model (paper II), keeping in mind that three animals in the 
ACA group were terminated prematurely due to significant oedema formation and 
inability to continue EVLP, lung oedema formation and decreasing lung compliance 
during EVLP occurred similarly with both techniques of EVLP. There were no significant 
differences between them with regards to lung function, inflammatory response, 
ischemia/reperfusion injury or histopathological changes.  
In the combined Copenhagen and Gothenburg clinical study (paper III), one of the larger 
studies of outcome after EVLP in DBD donors, time on ventilator and time in ICU after 
lung transplantation was significantly longer in the EVLP group. However, time to 
discharge, lung function at one year and survival in patients transplanted with lungs 
evaluated with EVLP did not differ significantly from patients transplanted with 
conventional donor lungs.   
In an attempt to identify risk factors during EVLP for poor outcome after lung 
transplantation (paper IV), we demonstrated no correlations between commonly 
measured variables during EVLP and short-term outcome. 
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FUTURE PERSPECTIVES 
 
 
EVLP as a means to evaluate marginal lungs is by now well established in clinical practice. 
The decision of accepting organs is moved from unfamiliar surroundings at the donor 
hospital to the home clinic, where decisions can be made in a controlled fashion after 
thorough evaluation. However, initiating an EVLP program is a substantial undertaking, 
and there has been an increasing interest in the concept of centralized EVLP centres, 
primarily in the USA. Since prolonged preservation times in conjunction with EVLP has 
been shown to be well tolerated, the extra time added to the transplantation process by 
such an arrangement, is considered acceptable. The basic idea is to provide EVLP services 
to transplant centres without their own expertize in the field, retrieving the lungs, 
performing EVLP and thereafter forwarding the approved organs to their respective 
transplantation centre. In this way, EVLP could be made more generally available, and 
benefit drawn from expertise gained at such high-volume centres, increasing quality and 
enabling research. There is of course also a commercial incentive, especially in the USA, 
in providing these services. Regulatory and process issues remain to be solved. 
As previously described, there is interest in finding reliable biomarkers to predict lung 
function after transplantation. None has so far reached clinical use, and the relatively 
limited time frame necessitating rapid analysis and test results of any potential biomarker 
is an obstacle that has to be overcome. 
Contemporary methods of evaluating lungs during EVLP mirror the overall performance 
of the organs. However, in many instances only a lobe or one lung may be pathological. 
Imaging modalities, such as real time CT, during EVLP might add to decision-making in 
the future. 
In line with the insights into the importance of a lung protective strategy during 
ventilation of patients in the ICU, there have been experimental studies reporting positive 
effects of certain ventilation strategies during EVLP. Further interest in this field and 
studies adapting the ventilation strategies used during clinical EVLP can be expected.  
Although the PaO2/FiO2 ratio has been and still is an important factor in assessing lung 
function, it is by now well known that it is a rather blunt tool, especially when using 
acellular perfusate. Focus will likely shift further to other parameters better and more 
reliably predicting outcome. Compliance is one parameter that has been attributed a 
greater significance lately. One emerging example is the PF-difference (the difference 
between PF-ratios at different fractions of inspired oxygen) mirroring the intrapulmonary 
shunt fraction, having been correlated with short-term outcome. 
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